# Medical Question & Answer

**Sample ID**: 3322a7d8-aa44-823f-087d-21900275ce2f
**Dataset Index**: 24745

---

## Question

Resume el tratamiento para neumonia adquirida en la comunidad en una paciente con cancer de mama

---

## Answer

> Let's see… What do we have here? The user is asking about the treatment of community-acquired pneumonia in a patient with breast cancer. Let's break this down step-by-step. First, I need to think about the patient's baseline immunologic risk and how breast cancer therapy modifies that risk. Then, I should verify the initial assessment priorities, including severity scoring and early diagnostics. Next, I will consider empiric antibiotic choices tailored to immunocompromise and local resistance patterns, followed by adjustments once cultures return. After that, I need to check supportive care, including oxygenation, fluids, and adjuncts. I will then examine special scenarios such as COVID-19 coinfection, neutropenia, and ICU transfer thresholds. Finally, I should confirm duration, follow-up, and how to integrate oncologic care without compromising cancer outcomes, making sure each step aligns with guidelines and available evidence.

> Let me first confirm the baseline risk profile. Patients with breast cancer often have treatment-related immunosuppression from chemotherapy, endocrine therapy, targeted agents, or immunotherapy, which increases susceptibility to infection and severity of community-acquired pneumonia, so I need to keep that front and center when choosing empiric therapy and monitoring intensity [^0f9dc56c] [^16730a11].

> Wait, let me verify the initial assessment priorities. I should obtain vital signs, oxygen saturation, and apply a validated severity score such as CURB-65 or PSI to guide site-of-care decisions, while also checking a complete blood count, renal and hepatic function, and inflammatory markers like CRP and procalcitonin to contextualize severity and guide therapy. In immunocompromised hosts, I should maintain a lower threshold for hospitalization and consider early blood cultures and sputum studies if productive, recognizing that delays in diagnostics can worsen outcomes in this population [^notfound].

> I need to ensure empiric antibiotic selection matches the immunocompromised state and local epidemiology. For a breast cancer patient with CAP, I should broaden empiric coverage beyond standard CAP regimens: a beta-lactam with antipseudomonal activity such as ceftazidime or piperacillin-tazobactam, plus a macrolide or doxycycline for atypical coverage, or alternatively a respiratory fluoroquinolone if beta-lactam allergy or intolerance is present. If MRSA risk is present, I should add vancomycin or linezolid, and if severe beta-lactam allergy exists, I can substitute with a carbapenem plus a fluoroquinolone, always aligning with local antibiograms and resistance data [^e4beec44] [^75556dc1] [^f649a2e3].

> Hold on, I should verify adjustments once cultures return. If cultures are negative but the patient is improving, I can de-escalate to standard CAP therapy; if positive, I will tailor to the identified pathogen and susceptibilities, and if cultures remain negative and there is no improvement, I should reconsider atypical pathogens, resistant organisms, or noninfectious etiologies and reassess the need for broader coverage or additional diagnostics [^notfound].

> Next, I should review supportive care. I will provide supplemental oxygen to maintain SpO2 at or above 92%, ensure adequate hydration while avoiding fluid overload, and use antipyretics for symptom control. In severe hypoxemia or respiratory distress, I should escalate to high-flow nasal cannula or noninvasive ventilation as appropriate, and I will monitor closely for deterioration given the higher risk of rapid decompensation in immunocompromised patients [^notfound].

> But wait, what if COVID-19 is in the differential. I should test for SARS-CoV-2 in all cancer patients with respiratory symptoms, because coinfection is not rare and alters both infection control and treatment decisions. If positive, I will layer COVID-19 management onto CAP care, including consideration of antivirals per current guidance and strict isolation protocols, and I will coordinate with oncology to adjust myelosuppressive therapy timing based on severity and testing status [^16730a11] [^0f9dc56c].

> I will now examine hematologic risk. If the patient is on or recently completed myelosuppressive therapy, I should have a low threshold to check for febrile neutropenia and initiate filgrastim when indicated, as G-CSF reduces the incidence of febrile neutropenia and infection-related complications in patients receiving myelosuppressive chemotherapy, which can materially change outcomes in this setting [^3ee40e56].

> Let me consider ICU transfer thresholds. I should escalate to intensive care for refractory hypoxemia requiring high-flow oxygen or noninvasive ventilation, hemodynamic instability, or progressive respiratory failure, and I should involve oncology early in discussions about goals of care and prognosis, since cancer patients with severe infections have higher mortality and benefit from coordinated critical care and oncologic input [^b432dcc1] [^f9015c72].

> I should double-check duration and follow-up. For uncomplicated CAP in an immunocompromised host, a total of 7 to 10 days is reasonable, extending to 10 to 14 days if response is slow or complications arise. I will reassess clinically at 48 to 72 hours and obtain repeat imaging if there is no improvement to exclude complications such as empyema or abscess, and I will coordinate with oncology to resume systemic therapy once the patient is clinically stable and afebrile for at least 48 hours [^notfound].

> Hold on, let's not jump to conclusions about cancer treatment interruptions. I need to balance infection control with oncologic benefit: for curative-intent therapy, I should avoid delays when possible; for palliative therapy, I may prioritize infection control and patient comfort. If chemotherapy was delayed due to infection, I will resume as soon as safely feasible and consider prophylactic G-CSF in subsequent cycles to mitigate recurrence of neutropenia and infection risk [^0f9dc56c] [^0f7dee4a].

> Let me reconsider the overall flow to ensure coherence. The plan is to stratify risk, apply severity tools, start broad empiric therapy aligned with immunocompromise, obtain early diagnostics, deliver supportive care with a low threshold for oxygen and ICU transfer, address COVID-19 and neutropenia proactively, tailor therapy to culture results, define appropriate duration, and coordinate oncology resumption, all while continuously reassessing for complications and response to therapy [^notfound].

---

En una paciente con cáncer de mama y neumonía adquirida en la comunidad (NAC), el tratamiento debe **individualizarse según el riesgo de neutropenia y la gravedad respiratoria**. En general, **la terapia empírica debe cubrir bacterias comunes de NAC y patógenos atípicos**, con ajuste según cultivos y sensibilidades. Si hay neutropenia febril o inmunosupresión significativa, ampliar a cobertura antipseudomona y considerar G-CSF según guía. Monitorizar estrechamente la oxigenación, la función renal/hepática y la respuesta clínica, y coordinar con oncología para ajustar la quimioterapia según el estado general y la recuperación respiratoria.

---

## Evaluación inicial y estratificación de riesgo

- **Evaluación clínica**: Valorar signos vitales, frecuencia respiratoria, saturación de oxígeno, estado de conciencia y comorbilidades.

- **Estratificación de riesgo**: Utilizar CURB-65 o PSI para decidir hospitalización y cuidados intensivos.

- **Pruebas diagnósticas**: Hemograma, bioquímica sanguínea, gasometría arterial, radiografía de tórax y, si es posible, tomografía computarizada de tórax.

- **Microbiología**: Cultivo de esputo, hemocultivos y, en caso de neutropenia, cultivo de lavado broncoalveolar.

---

## Consideraciones especiales en pacientes con cáncer de mama

- **Inmunosupresión**: La quimioterapia y la radioterapia aumentan el riesgo de infecciones graves, incluyendo NAC.

- **Neutropenia**: Es común y aumenta el riesgo de infecciones bacterianas graves, requiriendo cobertura antibiótica amplia y consideración de G-CSF.

- **Comorbilidades**: Frecuentes, como diabetes, enfermedad cardiovascular y EPOC, que complican el manejo.

---

## Tratamiento antimicrobiano empírico

| **Situación clínica** | **Tratamiento empírico recomendado** |
|-|-|
| NAC estándar (sin neutropenia) | - Amoxicilina-clavulanato o cefalosporina de 2.ª o 3.ª generación <br/> - Más macrólido o doxiciclina para cobertura atípica |
| NAC con neutropenia febril o inmunosupresión significativa | - Piperacilina-tazobactam o cefepima <br/> - Más vancomicina o linezolid para cobertura de MRSA <br/> - Considerar G-CSF según guía |
| Alergia a betalactámicos | - Levofloxacino o moxifloxacino <br/> - Más aztreonam o clindamicina según caso |

---

## Ajuste terapéutico según resultados microbiológicos

Una vez disponibles los resultados de cultivos y sensibilidades, **ajustar el tratamiento** para dirigirlo al patógeno identificado y minimizar la resistencia bacteriana.

---

## Medidas de soporte y monitorización

- **Oxigenoterapia**: Mantener saturación de oxígeno ≥ 92%.

- **Hidratación**: Corrección de desequilibrios hidroelectrolíticos.

- **Analgesia y antipiréticos**: Paracetamol o ibuprofeno para control de fiebre y dolor.

- **Monitorización**: Frecuente de signos vitales, gasometría arterial y parámetros de laboratorio.

---

## Coordinación con oncología

La quimioterapia debe **posponerse hasta la estabilización clínica y la resolución de la neutropenia**, si está presente. Se requiere seguimiento estrecho para detectar complicaciones y recaídas. La terapia de soporte y cuidados paliativos deben considerarse según el estado general y la etapa de la enfermedad.

---

## Pronóstico y complicaciones

El pronóstico depende de la **gravedad de la NAC**, la presencia de neutropenia, la respuesta al tratamiento antimicrobiano y el estado general de la paciente. Las complicaciones frecuentes incluyen insuficiencia respiratoria aguda, sepsis, shock séptico y fallo multiorgánico.

---

El tratamiento de la NAC en una paciente con cáncer de mama requiere un **enfoque multidisciplinario**, con cobertura antibiótica adecuada, monitorización estrecha y coordinación con oncología para optimizar el pronóstico.

---

## References

### A rectal cancer surgical decision aid is not enough: a qualitative study [^b83daabd]. Diseases of the Colon and Rectum (2022). Medium credibility.

Background

Rectal cancer patients often face complex surgical treatment decisions, but there are few available tools to aid in decision-making.

Objective

We aimed to identify content and delivery preferences of rectal cancer patients and colorectal surgeons to guide future surgical decision aid creation.

Design

Qualitative study: inductive thematic analysis of semi-structured interviews.

Setting

In-person and phone interviews.

Patients

We purposively sampled 15 rectal cancer survivors based on demographics and surgery type. Five caregivers also participated. We purposively selected 10 surgeons based on practice type and years of experience.

Interventions

Semi-structured interviews.

Main Outcome Measures

Major and minor themes for survivors and surgeons with thematic saturation.

Results

Interviews were a median of 61 minutes (41-93) for patients and 35 minutes (25-59) for surgeons. Nine survivors were younger than 65 years; 7 were female. Surgeons had been practicing for a mean of 10 years (SD 7.4), with 7 in academic and 3 in private settings. Participating survivors and surgeons wanted a comprehensive educational tool-not just a surgical decision aid. Survivors wanted more information on rectal cancer basics and lifestyle, care timelines, and resources during treatment. Surgeons thought patients mostly desired information about surgical options and bowel function. Both patients and surgeons wanted a tool that was personalized, simple, understandable, visually appealing, interactive, short, and in multiple formats.

Limitations

Results may not be generalizable due to selection bias of participants.

Conclusion

Rectal cancer survivors, their caregivers, and colorectal surgeons wanted an educational support tool that would address substantial educational needs through the continuum of disease rather than a surgical decision aid focusing on a discrete surgical choice only. See Video Abstract at http://links.lww.com/DCR/C20 .

Una Ayuda Para La Decisin Quirrgica Del Cncer De Recto No Es Suficiente Un Estudio Cualitativo

ANTECEDENTES:Los pacientes con cáncer de recto a menudo enfrentan decisiones de tratamiento quirúrgico complejas, pero hay pocas herramientas disponibles para ayudar en la toma de decisiones.OBJETIVO:Nuestro objetivo fue identificar el contenido y las preferencias de entrega de los pacientes con cáncer de recto y los cirujanos colorrectales para guiar la futura creación de ayuda para la toma de decisiones quirúrgicas.DISEÑO:Estudio cualitativo: análisis temático inductivo de entrevistas semiestructuradas.ESCENARIO:Entrevistas en persona y por teléfono.PACIENTES:Tomamos muestras intencionalmente de 15 sobrevivientes de cáncer de recto, según la demografía y el tipo de cirugía. También participaron cinco cuidadores. Seleccionamos intencionalmente a 10 cirujanos según el tipo de práctica y los años de experiencia.INTERVENCIONES:Entrevistas semiestructuradas.PRINCIPALES MEDIDAS DE RESULTADO:Temas principales y secundarios para sobrevivientes y cirujanos con saturación temática.RESULTADOS:Las entrevistas tuvieron una mediana de 61 minutos (41-93) para pacientes y 35 minutos (25-59) para cirujanos. Nueve sobrevivientes tenían menos de 65 años; siete eran mujeres. Los cirujanos habían estado ejerciendo una media de 10 años (DE 7,4), con siete en entornos académicos y 3 en entornos privados. Los sobrevivientes y cirujanos participantes querían una herramienta educativa comprensible, no solo una ayuda para la decisión quirúrgica. Los sobrevivientes querían más información sobre los conceptos básicos y el estilo de vida del cáncer de recto, los plazos de atención y los recursos durante el tratamiento. Los cirujanos pensaron que los pacientes en su mayoría deseaban información sobre las opciones quirúrgicas y la función intestinal. Tanto los pacientes como los cirujanos querían una herramienta que fuera personalizada, simple, comprensible, visualmente atractiva, interactiva, corta y en múltiples formatos.LIMITACIONES:Los resultados pueden no ser generalizables debido al sesgo de selección de los participantes.CONCLUSIÓN:Los sobrevivientes de cáncer rectal, sus cuidadores y los cirujanos colorrectales querían una herramienta de apoyo educativo que cubriera las necesidades educativas sustanciales a lo largo del tratamiento de la enfermedad en lugar de una ayuda para la decisión quirúrgica que se centre solo en una opción quirúrgica discreta. Consulte Video Resumen en http://links.lww.com/DCR/C20 . (Traducción-Dr. Yolanda Colorado ).

---

### Barium sulfate (vizumax HD) [^caccd7f8]. FDA (2021). Medium credibility.

La aspiración de grandes cantidades de suspensión de sulfato de bario puede causar neumonitis o granulomas nodulares de tejidos pulmonares intersticiales y ganglios linfáticos; asfixia y muerte han sido reportadas.

La bacteriemia transitoria puede ocurrir durante la administración rectal de la suspensión de sulfato de bario, y se ha informado de septicemia.

Una reacción alérgica leve y poco común sería la prurito generalizada, el eritema o la urticaria (aproximadamente 1 de cada 100.000 reacciones). Tales reacciones a menudo responderán a un antihistamínico. Las reacciones más graves (aproximadamente 1 en 500,000) pueden causar edema laríngeo, broncoespasmo o hipotensión.

Las reacciones graves que pueden requerir medidas de emergencia a menudo se caracterizan por vasodilatación periférica, hipotensión, taquicardia refleja, disnea, broncoespasmo, agitación, confusión y cianosis, que progresa hasta la inconsciencia. El tratamiento debe iniciarse de inmediato de acuerdo con el estándar de atención establecido.

---

### Fertility drugs and cancer: a guideline [^926d8f61]. Fertility and Sterility (2024). High credibility.

Fertility drugs and cancer guideline—methodological limitations in studying associations include inherently higher cancer risk in women who never conceived, risks from infertility-related factors (endometriosis and unopposed estrogens), the low incidence of most cancers, and that cancer diagnosis typically occurs years after fertility drug use. Based on available data, there appears to be no association between fertility medications and breast, colon, or cervical cancer, and there is no conclusive evidence that fertility medications increase uterine cancer risk, although women with infertility have a higher risk of uterine cancer. The guideline states there are insufficient data to comment on melanoma and non-Hodgkin lymphoma risk associated with fertility drug use. Counseling is emphasized: “Se debe informar a las mujeres que puede haber un mayor riesgo de cánceres de ovario invasivos y limítrofes, y cáncer de tiroides asociado con el tratamiento de fertilidad,” and it is difficult to determine whether this risk relates to underlying endometriosis, female infertility, or nulliparity.

---

### Barium sulfate (vizumax ENEM) [^9c61aa6c]. FDA (2021). Medium credibility.

CONTRAINDICACIONES: Este producto no debe utilizarse en pacientes con perforación gástrica o intestinal conocida o sospechada, pacientes con afecciones que pueden aumentar el riesgo de perforación; hipersensibilidad a los productos de sulfato de bario; sospecha de fístula traqueoesofágica; lesions obstructadoras del intestino delgado; estenosis pilórica; inflamación o lesiones neoplásicas del recto; o en pacientes que han tenido una biopsia rectal reciente.

16. Las suspensiones de sulfato de bario no deben usarse en niños con trastornos de la deglución o en recién nacidos con obstrucción duodenal o yeyunal completa o cuando se sospecha obstrucción distal del intestino delgado o del colon. La suspensión de sulfato de bario no se recomienda para bebés prematuros muy pequeños y bebés pequeños que requieren pequeños volúmenes de medios de contraste o para bebés y niños pequeños cuando existe la posibilidad de fugas del tracto gastrointestinal, como enterocolitis necrotizante, neumoperitoneo inexplicable, abdomen sin gas, otros perforación intestinal, perforación esofágica o anastomosis postoperatoria.

---

### Barium sulfate (vizumax HD) [^e6091d01]. FDA (2021). Medium credibility.

CONTRAINDICACIONES

CONTRAINDICACIONES: Este producto no debe utilizarse en pacientes con perforación gástrica o intestinal conocida o sospechada, pacientes con afecciones que pueden aumentar el riesgo de perforación; hipersensibilidad a los productos de sulfato de bario; sospecha de fístula traqueoesofágica; lesions obstructadoras del intestino delgado; estenosis pilórica; inflamación o lesiones neoplásicas del recto; o en pacientes que han tenido una biopsia rectal reciente.

Las suspensiones de sulfato de bario no deben usarse en niños con trastornos de la deglución o en recién nacidos con obstrucción duodenal o yeyunal completa o cuando se sospecha obstrucción distal del intestino delgado o del colon. La suspensión de sulfato de bario no se recomienda para bebés prematuros muy pequeños y bebés pequeños que requieren pequeños volúmenes de medios de contraste o para bebés y niños pequeños cuando existe la posibilidad de fugas del tracto gastrointestinal, como enterocolitis necrotizante, neumoperitoneo inexplicable, abdomen sin gas, otros perforación intestinal, perforación esofágica o anastomosis postoperatoria.

---

### Hyaluronic acid [^3c254249]. FDA (2020). Medium credibility.

Precautions and Warnings

* Si se observase derrame articular extraerlo antes de inyectar Maxiostenil.

* Es necesario seguir la técnica correcta de la inyección intraarticular en condiciones completamente asépticas.

Ver Instrucciones de uso y manipulación.

* Como en cualquier procedimiento intraarticular, es recomendable evitar la sobrecarga de la articulación

tratada, inmediatamente después de la inyección intraarticular.

* Los pacientes deben ser cuidadosamente examinados antes de la administración de Maxiostenil para

determinar posibles signos de inflamación agudos y el médico debe evaluar cuidadosamente la oportunidad del

inicio de la terapia.

* Se debe observar particular atención en pacientes con infecciones o alteraciones de la piel en zonas próximas

al punto de inyección para evitar la posibilidad de desarrollar artritis bacteriana.

* Guardar fuera del alcance de los niños.

---

### Síndromes cardiopulmonares (PDQ ®) [^3abf36ab]. NCI (2004). Low credibility.

El melanoma y el cáncer de pulmón de células no pequeñas fueron los cánceres más comunes que se trataron en este estudio. Curiosamente, la duración del tratamiento antes del comienzo de la neumonía fue bastante variable, con una mediana de tiempo hasta el inicio de 2, 8 meses. Además, la neumonía pareció presentarse más temprano en los pacientes que recibieron terapia combinada que en aquellos que recibieron monoterapia. . 23] Linfagitis carcinomatosa: un ensayo de corticoesteroides, por ejemplo, dexametasona. La dosis óptima no se conoce con claridad. En los cánceres sensibles debe pensarse en la posibilidad de usar quimioterapia. Obstrucción de la vena cava superior: quimioterapia para tumores sensibles, radioterapia, derivaciones, opioides para la disnea o corticoesteroides según sea apropiado en el contexto clínico.

Neumonitis relacionada con la inmunoterapia con inhibidores de puntos de control: para pacientes con grado 2 o superior de intensidad, suspensión del tratamiento, administración de corticoesteroides y seguimiento minucioso. Si la neumonitis empeora, es posible considerar la inmunosupresión adicional, aunque no está claro el beneficio. Otros investigadores examinaron el efecto de otras modalidades de administración de oxígeno para pacientes de cáncer con disnea, tales como las siguientes: . **En varios ensayos aleatorizados controlados, se observó que la BiPAP alivia la disnea en pacientes de cáncer hospitalizados; en particular, en pacientes con hipoventilación. Estas intervenciones son opciones razonables para los pacientes con hipoxemia y disnea resistente pese al uso de oxígeno suplementario de flujo bajo.

En un estudio aleatorizado con enmascaramiento simple se indicó que la combinación de dos medicamentos programados y, según se necesite, un medicamento para los episodios de disnea intercurrente es más eficaz que las otras combinaciones evaluadas, pero este abordaje necesita estudiarse más. .

---

### Benzocaine (gelato topical anesthetic) [^be2abaa4]. FDA (2022). Medium credibility.

Advertencias

Advertencia de metahemoglobinemia: el uso de este producto puede causar metahemoglobinemia, una afección grave que debe tratarse con pron_tud ya que reduce la cantidad de oxígeno transportado en la sangre. Esto puede ocurrir incluso si ha usado este product anteriormente. Detenga su uso y busque atención médica inmediata si observa que usted o un niño bajo su cuidado presenta:

• piel pálida, gris o azul (cianosis)

• dolor de cabeza

• frecuencia cardíaca rápida

• dificultad para respirar

• mareos o aturdimiento

• fatiga o falta de energía

Alerta de alergia: 

No use en pacientes con antecedentes de alergias a anestésicos locales como procaína, butacaína, benzocaína u otros anestésicos de "caína".

No utilice: 

• durante más de 7 días a menos que lo indique un médico. Si los síntomas de dolor en la boca no mejoran en 7 días; la irritación, el dolor o el enrojecimiento persisten o empeoran; o si se desarrolla hinchazón, sarpullido o fiebre, consulte a su médico de inmediato.

• para la dentición

• en niños menores de 2 años

Cuando utilice este producto 

Evite el contacto con los ojos. En caso que esto ocurra, enjuague con abundante agua fresca.

No exceda la dosis recomendada. 

Si se ingiere accidentalmente más de lo recomendado para el dolor, obtenga ayuda médica o

comuníquese con un Centro de control de envenenamiento de inmediato.

---

### Barium sulfate (vizumax ENEM) [^1496e93b]. FDA (2021). Medium credibility.

PRECAUCIONES

General: los procedimientos que implican el uso de medios de contraste radiopacos deben llevarse a cabo bajo la dirección de personal con la capacitación requerida y con un conocimiento profundo del procedimiento particular que se realizará. Los antecedentes de asma bronquial, atopia, como lo evidencian la fiebre del heno y el eccema, o una reacción previa a un agente de contraste, merecen especial atención. Se debe tener precaución con el uso de medios radiopacos en pacientes severamente debilitados y en aquellos con hipertensión marcada o enfermedad cardiaca avanzada. No se recomienda la ingestión de bario en pacientes con antecedentes de aspiración de alimentos. Tenga cuidado si administra este producto a pacientes en quienes se desconoce la integridad del mecanismo de deglución. Si se aspira bario en la laringe, se debe interrumpir inmediatamente la administración posterior. Después de cualquier estudio con bario del tracto gastrointestinal, puede ser importante rehidratar al paciente lo más rápido posible para evitar la impactación del bario. Para evitar la impactación del bario en el colon, también puede ser necesario el uso de laxantes suaves como leche de magnesia o lactulosa después de la finalización del examen. Estos laxantes suaves se recomiendan de forma rutinaria y en pacientes con antecedentes de estreñimiento a menos que esté clínicamente contraindicado.

---

### Filgrastim (Neupogen) [^3ee40e56]. FDA (2025). Medium credibility.

14.1	Patients with Cancer Receiving Myelosuppressive Chemotherapy

The safety and efficacy of NEUPOGEN to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs were established in a randomized‚ double-blind‚ placebo-controlled trial conducted in patients with small cell lung cancer (Study 1).

In Study 1, patients received up to 6 cycles of intravenous chemotherapy including intravenous cyclophosphamide and doxorubicin on day 1; and etoposide on days 1, 2, and 3 of 21 day cycles. Patients were randomized to receive NEUPOGEN (n = 99) at a dose of 230 mcg/m2(4 to 8 mcg/kg/day) or placebo (n = 111). Study drug was administered subcutaneously daily beginning on day 4, for a maximum of 14 days. A total of 210 patients were evaluable for efficacy and 207 were evaluable for safety. The demographic and disease characteristics were balanced between arms with a median age of 62 (range 31 to 80) years; 64% males; 89% Caucasian; 72% extensive disease and 28% limited disease.

The main efficacy endpoint was the incidence of febrile neutropenia. Febrile neutropenia was defined as an ANC < 1,000/mm3and temperature > 38.2°C. Treatment with NEUPOGEN resulted in a clinically and statistically significant reduction in the incidence of infection‚ as manifested by febrile neutropenia, 40% for NEUPOGEN-treated patients and 76% for placebo-treated patients (p < 0.001). There were also statistically significant reductions in the incidence and overall duration of infection manifested by febrile neutropenia; the incidence, severity and duration of severe neutropenia (ANC < 500/mm3); the incidence and overall duration of hospital admissions; and the number of reported days of antibiotic use.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^2d5a817d]. Developmental Medicine and Child Neurology (2025). Medium credibility.

CRITICA DE LA EVIDENCIA DISPONIBLE

Una limitación importante en muchos de los estudios disponibles es el pequeño tamaño de muestra, con sólo un poco más de un tercio de los estudios incluyendo más de 10 pacientes (mediana = 8.5, rango 1–45). Típicamente, se realizan estudios pequeños cada vez que se prueba el enfoque CO‐OP en una nueva población, en un esfuerzo por proporcionar una prueba de concepto. El principal grupo de niños en los que CO‐OP ha sido validado y se ha establecido como prueba de concepto (y más allá para algunos grupos) incluye TDC, autismo, parálisis cerebral (PC), lesión cerebral adquirida, función ejecutiva y trastornos hipercinéticos de inicio en la infancia, incluyendo trastornos raros de distonía genética.

La literatura muestra que el enfoque de investigación es predominantemente el uso de estudios de caso único con replicas. Aunque se ha informado del uso de estudios de caso único con múltiples líneas base en 10 estudios de CO‐OP, no todos proporcionaron suficientes replicas (mínimo de N‐de‐1 con tres replicas),,,,,,,según guías establecidas.Esto ha permitido el desarrollo de este enfoque con diversas poblaciones, incluyendo trastornos raros.

Sin embargo, se debe prestar más atención a enfoques más robustos para establecer la eficacia mediante un ensayo definitivo (Recomendación 1).

---

### Solucion aditiva para plaquetas 3 (solucion interSol) [^c7442c4a]. FDA (2021). Medium credibility.

A los pacientes se les prescribieron transfusiones de plaquetas en acatamiento de la metodología normal de la institución. El tipo de plaqueta que recibió el paciente fue determinado por el inventario de la institución al momento en que se prescribió la transfusión. El personal de la institución observó al receptor de la transfusión de plaquetas en acatamiento de sus procedimientos normales. Los síntomas y las evidencias de una reacción que, posiblemente, estuvo relacionada con la transfusión se registraron utilizando los sistemas de preparación de informes existentes. En el análisis final se incluyó un total de 14 005 transfusiones procedentes de 6 instituciones donde se realizó el estudio. Se administraron un total de 4160 transfusiones de plaquetas con InterSol a un total de 1444 pacientes y se administraron 9845 transfusiones de plaquetas con plasma a un total de 2202 pacientes. Se registraron 165 reacciones adversas que fueron adjudicadas por el comité CEC. De ese número, 23 eventos fueron asociados con plaquetas con InterSol y 142 eventos fueron asociados con plaquetas con plasma.

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^b432dcc1]. The Oncologist (2020). Medium credibility.

Admission Criteria for Patients with Cancer

SARS‐CoV‐2–infected patients with cancer are especially vulnerable to inadequate management of COVID‐19 because this condition is still associated with inexorable incurability or near death, even among certain HCP. However, many patients with cancer can benefit from intensive care when the evolution of pneumonia or any other complication so advises. Decisions regarding care should be made based on each patient's prognosis. Overall, decisions regarding admission to ICU will greatly benefit from a consultation with the patient's oncologist, who has the most complete information of the specific disease's natural history, including its prognosis and the patient's life expectancy. For instance, the following patients with BC would benefit from ICU admission:
Previously diagnosed patients, already operated, disease free, and currently being followed up.
Patients currently on treatment with (neo) adjuvant therapies with curative intention.
Patients whose single metastasis has been surgically removed, who are being followed up or in treatment with “adjuvant” therapy with a good prognosis for survival.
Patients with metastatic disease on treatment with targeted therapies in response, with an expected median survival ≥5 years.
Patients in any other circumstances, in response, with an expected prolonged survival, evaluated together with oncology.

---

### Prevention and control strategies for the diagnosis and treatment of cancer patients during the COVID-19 pandemic [^a47d2633]. British Journal of Cancer (2020). Medium credibility.

COVID-19 has had a major impact worldwide due to its high infectiousness. Patients with cancer are more susceptible to infection and more likely to have severe events than other patients. This paper proposes management strategies for cancer patients that are beneficial for pandemic control and reduce the impact of the pandemic on cancer patients.

---

### British thoracic society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) [^1b0b0371]. BMJ Open Respiratory Research (2017). Medium credibility.

Online appendices

Available at:

Appendix 1: Clinical questions and literature search strategy

Appendix 2: Evidence tables

Appendix 3: Patient information

---

### Barium sulfate (vizumax HD) [^098635b2]. FDA (2021). Medium credibility.

PRECAUCIONES

PRECAUCIONES: General: los procedimientos que implican el uso de medios de contraste radiopacos deben llevarse a cabo bajo la dirección de personal con la capacitación requerida y con un conocimiento profundo del procedimiento particular que se realizará. Los antecedentes de asma bronquial, atopia, como lo evidencian la fiebre del heno y el eccema, o una reacción previa a un agente de contraste, merecen especial atención. Se debe tener precaución con el uso de medios radiopacos en pacientes severamente debilitados y en aquellos con hipertensión marcada o enfermedad cardiaca avanzada. No se recomienda la ingestión de bario en pacientes con antecedentes de aspiración de alimentos. Tenga cuidado si administra este producto a pacientes en quienes se desconoce la integridad del mecanismo de deglución. Si se aspira bario en la laringe, se debe interrumpir inmediatamente la administración posterior. Después de cualquier estudio con bario del tracto gastrointestinal, puede ser importante rehidratar al paciente lo más rápido posible para evitar la impactación del bario. Para evitar la impactación del bario en el colon, también puede ser necesario el uso de laxantes suaves como leche de magnesia o lactulosa después de la finalización del examen. Estos laxantes suaves se recomiendan de forma rutinaria y en pacientes con antecedentes de estreñimiento a menos que esté clínicamente contraindicado.

---

### Drinking water advisory communication toolbox. updated 2013 [^c8e82716]. CDC (2013). Medium credibility.

Hoja informativa durante una advertencia para hervir el agua—higiene personal, dientes, trastes, lavandería y mascotas: Debe tener cuidado de no tragar agua al bañarse en la tina o la regadera, y Tenga cuidado al bañar a bebés y a niños pequeños; Considere darles baños de esponja para evitar que traguen agua. Para lavarse los dientes use agua hervida o embotellada. Se puede usar el lavador de platos sin problemas si el agua llega a una temperatura de por lo menos 160 grados, o si el lavador de platos tiene un ciclo de sanitación. Para lavar los trastes a mano, Lave y enjuague los trastes como lo hace normalmente, pero con agua caliente; en otra pileta, agregue 1 cucharadita de cloro para uso doméstico, sin aromatizante, por cada galón de agua tibia, luego Remoje los trastes ya enjuagados en el agua con cloro por lo menos durante un minuto y Deje que los trastes se sequen por completo al aire. Puede lavar la ropa sin problemas de la forma en que acostumbra a hacerlo. Las mascotas caseras sufren de las mismas enfermedades que los humanos y Es una buena idea darles agua hervida para tomar. Para obtener más información, comuníquese con Preparación personal y almacenamiento de agua segura—Los CDC ofrecen una guía acerca de la cantidad de agua necesaria para la buena salud, así como la forma de preparar y almacenar el agua segura antes y durante una emergencia, y con Higiene y lavado de manos—Los CDC ofrecen una guía acerca métodos de higiene alternativos cuando no hay agua disponible o está contaminada.

---

### Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^1afabf8d]. Annals of Oncology (2024). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer, adjuvant systemic therapy, HER2+, ESMO 2024 guidelines recommend to offer adjuvant chemotherapy combined with 1 year of anti-HER2 therapy in patients with pathological stage II-III breast cancer treated with initial surgery.

---

### Abdominal surgical procedures in adult patients with cystic fibrosis: what are the risks? [^b7e736ae]. Diseases of the Colon and Rectum (2022). Medium credibility.

BACKGROUND:

With advances in medical care, patients with cystic fibrosis are more commonly living into adulthood, yet there are limited data describing the need for GI surgery and its outcomes in adult cystic fibrosis patients.

OBJECTIVE:

We aim to use a national administrative database to evaluate trends in abdominal GI surgery and associated postoperative outcomes among adult cystic fibrosis patients.

DESIGN:

This was a national retrospective cohort study.

SETTING:

A national all-payor administrative database from 2000 to 2014 was used.

PATIENTS:

Patients included adults (age ≥18 years) with cystic fibrosis undergoing abdominal GI surgery.

MAIN OUTCOME MEASURES:

The primary outcome was trend over time in number of surgical admissions. Secondary outcomes included morbidity and mortality by procedure type.

RESULTS:

We identified 3075 admissions for abdominal surgery, of which 28% were elective. Major GI surgical procedures increased over the study period (p < 0.01), whereas appendectomy and cholecystectomy did not demonstrate a clear trend (p = 0.90). The most common procedure performed was cholecystectomy (n = 1280; 42%). The most common major surgery was segmental colectomy (n = 535; 18%). Obstruction was the most common surgical indication (n = 780; 26%). For major surgery, in-hospital mortality was 6%, morbidity was 37%, and mean length of stay was 15.9 days (SE 1.2).

LIMITATIONS:

The study is limited by a lack of granular physiological and clinical data within the administrative data source.

CONCLUSIONS:

Major surgical admissions for adult patients with cystic fibrosis are increasing, with the majority being nonelective. Major surgery is associated with significant morbidity, mortality, and prolonged length of hospital stay. These findings may inform perioperative risk for adult patients with cystic fibrosis in need of GI surgery. See Video Abstract at.

PROCEDIMIENTOS QUIRÚRGICOS ABDOMINALES EN PACIENTES ADULTOS CON FIBROSIS QUÍSTICA: ¿CUÁLES SON LOS RIESGOS?

ANTECEDENTES:

Con los avances en la medicina, los pacientes con fibrosis quística viven más comúnmente hasta la edad adulta, pero hay datos escasos que describan la necesidad de cirugía gastrointestinal y sus resultados en pacientes adultos con fibrosis quística.

OBJETIVO:

Nuestro objetivo es utilizar una base de datos administrativa nacional para evaluar las tendencias en la cirugía gastrointestinal abdominal y los resultados posoperatorios asociados entre los pacientes adultos con fibrosis quística.

DISEÑO:

Estudio de cohorte retrospectivo nacional.

AJUSTE:

Base de datos administrativa nacional de todas las instituciones pagadoras desde 2000 a 2014.

PACIENTES:

Todos los pacientes adultos (edad> 18) con fibrosis quística sometidos a cirugía gastrointestinal abdominal.

PRINCIPALES MEDIDAS DE RESULTADO:

El resultado primario fue la tendencia a lo largo del tiempo en el número de ingresos quirúrgicos. Los resultados secundarios incluyeron morbilidad y mortalidad por tipo de procedimiento.

RESULTADOS:

Identificamos 3.075 ingresos por cirugía abdominal de los cuales el 28% fueron electivos. Los procedimientos quirúrgicos gastrointestinales mayores aumentaron durante el período de estudio (p <0,01) mientras que la apendicectomía y la colecistectomía no demostraron una tendencia clara (p = 0,90). El procedimiento realizado con mayor frecuencia fue la colecistectomía (n = 1.280; 42%). La cirugía mayor más común fue la colectomía segmentaria (n = 535; 18%). La obstrucción fue la indicación quirúrgica más común (n = 780; 26%). Para la cirugía mayor, la mortalidad hospitalaria fue del 6%, la morbilidad del 37% y la estadía media de 15,9 días (EE 1,2).

LIMITACIONES:

El estudio está limitado por la falta de datos clínicos y fisiológicos granulares dentro de la fuente de datos administrativos.

CONCLUSIONES:

Los ingresos quirúrgicos mayores de pacientes adultos con fibrosis quística están aumentando y la mayoría no son electivos. La cirugía mayor se asocia con una morbilidad y mortalidad significativas y una estancia hospitalaria prolongada. Estos hallazgos pueden informar el riesgo perioperatorio para pacientes adultos con fibrosis quística que necesitan cirugía gastrointestinal. Consulte Video Resumen en. (Traducción—Dr. Felipe Bellolio)

---

### Diagnosis and treatment of non-muscle invasive bladder cancer: AUA / SUO guideline [^390792b9]. The Journal of Urology (2016). Medium credibility.

Risk stratification in NMIBC—The European Organization for Research and Treatment of Cancer (EORTC) risk calculator, based on the combined data from seven trials, provides a probability of recurrence and progression at one and five years using clinical and pathologic variables; important factors for recurrence include prior recurrence rate, number of tumors, and tumor size, while for progression they include T-stage, presence of CIS, and grade; a second tool is that developed by the Spanish Urological Club for Oncological Treatment/Club Urologico Espanol de Tratamiento Oncologico (CUETO); both tools are limited by lack of applicability to current patient populations because few patients from the development cohort received BCG maintenance, underwent re-staging transurethral resection, or received single-dose post-operative mitomycin C; an updated EORTC nomogram analyzed a cohort of patients treated with one to three years of BCG but lacked patients with CIS and was limited by absence of routine re-resection; additionally, the EORTC risk calculator utilizes the 1973 WHO grading system to generate risk probabilities as opposed to the 2004 version, and the EORTC risk tables are commonly not considered in the U.S.

---

### Impact of definitive chemoradiation on quality-of-life changes for patients with anal cancer: long-term results of a prospective study [^73c0f715]. Diseases of the Colon and Rectum (2022). Medium credibility.

Background

Maintaining and improving quality of life (QOL) are important goals of anal cancer management. This disease is generally curable, with many long-term survivors.

Objective

Long-term QOL after chemoradiation for patients with anal cancer was evaluated.

Design

This was a prospective cohort study.

Settings

This study used data from a prospective study of patients with anal cancer who were treated with chemoradiation between 2008 and 2013.

Patients

Patients with anal cancer who were treated with image-guided intensity-modulated radiation therapy were included.

Interventions

English-speaking patients completed European Organization for Research and Treatment of Cancer cancer-specific (C30) and site-specific (CR29) QOL questionnaires at baseline, at end of radiation, at 3 and 6 months, and then annually.

Main Outcomes Measures

Long-term QOL was evaluated clinically (a change in score of ≥10 points was considered clinically significant) and statistically (using repeated-measurement analysis) by comparing the subscale scores at 1, 2, and 3 years with baseline scores. Subanalysis compared patients who received a radiation dose of 45 to 54 Gy versus 63 Gy.

Results

Ninety-six patients were included (median follow-up of 56.5 months). The symptom and functional scales showed a clinically significant decline at the end of treatment with improvement by 3 months after treatment. There was a long-term statistically significant decline in dyspnea, body image, bowel embarrassment, fecal incontinence, and hair loss, and there was long-term statistically and clinically significant worsening of impotence. Higher radiation dose (63 Gy) was not associated with significantly worse QOL.

Limitations

Limitations included single-institution, single-arm study design, and lack of dose reconstruction (ie, analyses were based on prescribed, rather than delivered, dose).

Conclusions

Patients with anal cancer treated with chemoradiation reported recovery of overall QOL to baseline levels. Specific symptoms remained bothersome, emphasizing the need to address and manage the chemoradiation-induced symptoms, during treatment and in the long term. See Video Abstract at http://links.lww.com/DCR/B905.

Impacto De La Quimiorradiacin Definitiva En Cambios En La Calidad De Vida De Los Pacientes Con Cncer Anal Resultados A Largo Plazo De Un Estudio Prospective

ANTECEDENTES:Mantener y mejorar la calidad de vida son objetivos importantes del tratamiento del cáncer anal, ya que esta enfermedad generalmente es curable, con muchos sobrevivientes a largo plazo.OBJETIVO:Se evaluó la calidad de vida a largo plazo después de la quimiorradiación en pacientes con cáncer anal.DISEÑO:Este fue un estudio de cohorte prospectivo.ENTORNO CLINICO:Utilizamos datos de un estudio prospectivo en pacientes con cáncer anal tratados con quimiorradiación entre 2008-2013.PACIENTES:Los pacientes con cáncer anal fueron tratados con radioterapia de intensidad modulada guiada por imágenes.INTERVENCIONES:Los pacientes de habla inglesa completaron los cuestionarios de calidad de vida específicos de cáncer (C30) y específicos del sitio (CR29) de la Organización Europea para la Investigación y el Tratamiento del Cáncer al inicio, al final de la radiación, 3 y 6 meses, y luego anualmente.PRINCIPALES MEDIDAS DE RESULTADOS:Se evaluó a largo plazo la calidad de vida clínicamente (un cambio en la puntuación de ≥10 puntos se consideraron clínicamente significativo) y estadísticamente (usando análisis de medición repetida) comparando las subescalas de puntuación al 1, 2, y 3 años. Con puntuaciones de referencia. El subanálisis comparó pacientes que recibieron 45-54 Gy versus 63 Gy.RESULTADOS:Se incluyeron un total de 96 pacientes (mediana de seguimiento: 56,5 meses). La mayoría de las escalas funcionales y de síntomas mostraron una disminución clínicamente significativa al final del tratamiento con una mejoría a los 3 meses posteriores al tratamiento. Hubo una disminución estadísticamente significativa a largo plazo en disnea, imagen corporal, vergüenza intestinal, incontinencia fecal y pérdida de cabello; y hubo un empeoramiento a largo plazo estadística y clínicamente significativo en impotencia. La dosis de radiación más alta (63 Gy) no se asoció con una calidad de vida significativamente peor.LIMITACIONES:Institución única, diseño de estudio de un solo brazo y falta de recomposición de la dosis (es decir, los análisis se basan en la dosis prescrita, en lugar de la administrada).CONCLUSIÓNES:Los pacientes con cáncer anal tratados con quimiorradiación reportaron una recuperación de la QOL en general a los niveles de base. Síntomas específicos siguieron siendo molestos, lo que enfatiza la necesidad de resolver y tartar los síntomas inducidos por la quimiorradiación no solo durante el tratamiento, sino a largo plazo. Consulte Video Resumen en http://links.lww.com/DCR/B905. (Traducción- Dr. Francisco M. Abarca-Rendon).

---

### Acetylcysteine injection (acetylcysteine) [^cd127b11]. FDA (2021). Medium credibility.

4 CONTRAINDICATIONS

Acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see Warnings and Precautions (5.1)] .

Patients with a previous hypersensitivity reaction to acetylcysteine. (4)

---

### Effects of adjuvant therapy compliance and anastomotic leakage on the oncologic outcomes of patients with rectal cancer after curative resection [^e24494be]. Diseases of the Colon and Rectum (2021). Medium credibility.

BACKGROUND:

Anastomotic leakage might be directly or indirectly related to the prognosis of patients with rectal cancer.

OBJECTIVE:

This study aimed to investigate whether anastomotic leakage affects the oncologic outcomes in patients with rectal cancer.

DESIGN:

This was a retrospective analysis of prospectively collected data.

SETTINGS:

This study was conducted at a teaching hospital between January 2009 and December 2013.

PATIENTS:

Patients who underwent curative resection for primary rectal cancer were included.

MAIN OUTCOME AND MEASURE:

Kaplan–Meier analyses were used to evaluate disease-free survival and overall survival.

RESULTS:

The overall incidence of anastomotic leakage was 2.7% (107/3865). Local recurrence was more frequent in patients with anastomotic leakage than in those without (14.0% vs 6.7%; p = 0.007). By multivariate analysis, anastomotic leakage was associated with increased local recurrence rate (p = 0.014) and poorer overall survival (p = 0.011). In subgroup analysis, compared with other pathologic risk factors, anastomotic leakage was associated with higher occurrence of local and distant recurrence in patients with stage II rectal cancer (p = 0.031 and <0.001). In patients with stage III rectal cancers, adjuvant therapy was more likely to be delayed or canceled in those experiencing anastomotic leakage (63 vs 39 d, p < 0.001; 37.3% vs 66.7%, p < 0.001). In addition, this patient group had the worst survival outcome when compared with those without anastomotic leakage and those with timely adjuvant therapy (5-year disease-free survival rate, p = 0.013; 5-year overall survival rate, p = 0.001).

LIMITATIONS:

This study is limited by its retrospective nature.

CONCLUSIONS:

There was a robust association between anastomotic leakage and local recurrence, while also potentially affect long-term survival of the patient group. Delayed or cancelled adjuvant therapy administration because of anastomotic leakage may partly account for the poorer survival in those patients with advanced rectal cancer. See Video Abstract at.

EFECTOS DE OBSERVANCIA DE TERAPIA ADYUVANTE Y FUGA ANASTOMÓTICA, EN RESULTADOS ONCOLÓGICOS DE PACIENTES CON CÁNCER RECTAL, DESPUÉS DE UNA RESECCIÓN CURATIVA

ANTECEDENTES:

La fuga anastomótica podría estar relacionada directa o indirectamente, con el pronóstico de los pacientes con cáncer de recto.

OBJETIVO:

El estudio tuvo como objetivo investigar si la fuga anastomótica afecta los resultados oncológicos, en pacientes con cáncer de recto.

DISEÑO:

Fue un análisis retrospectivo de datos recolectados prospectivamente.

AJUSTE:

El estudio se realizó en un hospital universitario entre enero de 2009 y diciembre de 2013.

PACIENTES:

Pacientes sometidos a resección curativa por cáncer rectal primario.

PRINCIPALES MEDIDAS DE RESULTADO:

Se utilizaron análisis de Kaplan-Meier para evaluar la supervivencia libre de enfermedad y supervivencia general.

RESULTADOS:

La incidencia global de fuga anastomótica fue del 2,7% (107/3865). La recurrencia local fue más frecuente en pacientes con fuga anastomótica, que en aquellos sin ella (14,0% frente a 6,7%, p = 0,007). Por análisis multivariado, la fuga anastomótica se asoció con una mayor tasa de recurrencia local (p = 0,014) y una peor supervivencia general (p = 0,011). En el análisis de subgrupos, en comparación con otros factores de riesgo patológicos, la fuga anastomótica se asoció con una mayor incidencia de recidiva local y a distancia en pacientes con cáncer rectal en estadio II (p = 0,031 y <0,001, respectivamente). En pacientes con cáncer rectal estadio III, la terapia adyuvante tuvo más probabilidades de retrasarse o cancelarse en aquellos que sufrían fuga anastomótica (63 vs 39 días, p <0,001; 37,3% vs 66,7%, p <0,001). Y este grupo de pacientes tuvo el peor resultado de supervivencia en comparación con aquellos sin fuga anastomótica y aquellos con terapia adyuvante oportuna (tasa de supervivencia libre de enfermedad a 5 años, p = 0,013; tasa de supervivencia global a 5 años, p = 0,001).

LIMITACIONES:

El estudio está limitado por su naturaleza retrospectiva.

CONCLUSIONES:

Hubo una sólida asociación entre la fuga anastomótica y la recurrencia local, mientras que también afecta potencialmente la supervivencia a largo plazo, del grupo de pacientes. La administración de terapia adyuvante retrasada o cancelada debido a una fuga anastomótica, puede explicar en parte, la menor supervivencia en aquellos pacientes con cáncer rectal avanzado. Consulte Video Resumen en.

---

### Clinical validity of tumor-informed circulating tumor DNA analysis in patients undergoing surgery of colorectal metastases [^73267e01]. Diseases of the Colon and Rectum (2023). Medium credibility.

Background

Accurate biomarkers to monitor tumor load and response in metastatic colorectal cancer patients undergoing surgery could optimize treatment regimens.

Objective

This study aimed to explore the clinical validity of tumor-informed quantification of circulating tumor DNA in blood using ultradeep sequencing.

Design

Resection specimens from 53 colorectal cancer patients were analyzed for tumor-specific mutations in 15 genes. These mutations were used to measure the presence of circulating tumor DNA in preoperatively collected plasma samples using hybrid capture-based sequencing. Additional postoperative measurements were performed 1 week after surgery in 16 patients.

Settings

The study was conducted at the Radboud University Medical Center.

Patients

A total of 53 colorectal cancer patients undergoing surgery of metastases were included.

Main Outcome Measures

The detection of circulating tumor DNA.

Results

At least 1 tumor-specific mutation was detected in all tumor samples. In preoperative plasma samples, circulating tumor DNA was detected in 88% (37/42) of systemic treatment-naïve patients and in 55% (6/11) of patients who received preoperative chemotherapy. More specifically, circulating tumor DNA was detected in 0% (0/3) of cases with a subtotal or partial pathologic response and in 75% (6/8) of cases without a pathologic response in the resection specimen ( p = 0.06). In postoperative plasma samples, circulating tumor DNA was detected in 80% (4/5) of patients with an incomplete resection and in 0% (0/11) of those with a complete resection ( p = 0.003).

Limitations

The study was limited by the heterogeneity of the cohort and the small number of postoperative plasma samples.

Conclusions

These data indicate that tumor-informed circulating tumor DNA detection in the plasma of patients undergoing surgery for metastatic colorectal cancer is feasible and may have clinical value in response monitoring and predicting residual disease. Prospective studies are needed to establish the clinical utility of circulating tumor DNA analysis to guide treatment decisions in these patients. See Video Abstract at http://links.lww.com/DCR/B990 .

Validez Clnica Del Anlisis De Adn Del Tumor Circulante Informado Por El Tumor En Pacientes Sometidos A Ciruga De Metstasis Colorrectales

ANTECEDENTES:Los biomarcadores precisos para monitorear la carga tumoral y la respuesta en pacientes con cáncer colorrectal metastásico que se someten a cirugía podrían optimizar los regímenes de tratamiento.OBJETIVO:Este estudio explora la validez clínica de la cuantificación informada por el tumor del ADN tumoral circulante en sangre mediante secuenciación ultraprofunda.DISEÑO:Se analizaron muestras de resección de 53 pacientes con cáncer colorrectal en busca de mutaciones específicas del tumor en quince genes. Estas mutaciones se usaron para medir la presencia de ADN tumoral circulante en muestras de plasma recolectadas antes de la operación usando secuenciación basada en captura híbrida. Se realizaron mediciones postoperatorias adicionales una semana después de la cirugía en dieciséis pacientes.AJUSTES:El estudio se realizó en el centro médico de la universidad de Radboud.PACIENTES:Se incluyeron un total de 53 pacientes con cáncer colorrectal sometidos a cirugía de metástasis.PRINCIPALES MEDIDAS DE RESULTADO:La detección de ADN tumoral circulante.RESULTADOS:Se detectó al menos una mutación específica de tumor en todas las muestras de tumor. En muestras de plasma preoperatorias, se detectó ADN tumoral circulante en el 88% (37/42) de los pacientes sin tratamiento sistémico previo y en el 55% (6/11) de los pacientes que recibieron quimioterapia preoperatoria. Más concretamente, en el 0% (0/3) de los casos con respuesta patológica subtotal o parcial y en el 75% (6/8) de los casos sin respuesta patológica en la pieza de resección ( p = 0,06). En muestras de plasma postoperatorio se detectó ADN tumoral circulante en el 80% (4/5) de los pacientes con una resección incompleta y en el 0% (0/11) de los que tenían resección completa ( p = 0,003).LIMITACIONES:El estudio estuvo limitado por la heterogeneidad de la cohorte y el pequeño número de muestras de plasma postoperatorias.CONCLUSIONES:Estos datos indican que la detección de ADN tumoral circulante informado por el tumor en el plasma de pacientes sometidos a cirugía por cáncer colorrectal metastásico es factible y puede tener valor clínico en el control de la respuesta y la predicción de la enfermedad residual. Se necesitan estudios prospectivos para establecer la utilidad clínica del análisis de ADN tumoral circulante para guiar las decisiones de tratamiento en estos pacientes. Consulte Video Resumen en http://links.lww.com/DCR/B990 . (Traducción-Dr. Mauricio Santamaria ).

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^0f9dc56c]. The Oncologist (2020). Medium credibility.

Introduction

Breast cancer (BC) is the malignancy with the highest incidence and prevalence among women in Spain [1]. Although the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus is capturing the world's attention and most of its health care resources, patients with BC still require adequate clinical management. However, patients with cancer may be more susceptible to infection with SARS‐CoV‐2 and, if infected, at a higher risk of serious respiratory complications due to treatment‐ or tumor‐related immunosuppression or to disease‐related malnutrition [2].

The organizational restructuring put in place to deal with the COVID‐19 patient care crisis has translated into deeply reduced availability of operating rooms, consultations, imaging tests, and other routine activities. Furthermore, most oncology‐related personnel are being referred to COVID‐19 patient care or to self‐isolation when infected.

In the context of this pandemic, it is imperative to rethink the risk/benefit ratio of each cancer treatment and each in‐hospital visit aiming at minimizing pandemic‐associated risks while maintaining adequate treatment efficacy. A stratification of the benefit/risk ratios for different patients with BC in different situations is difficult in the absence of more complete information about the real impact the different treatments could have on the risk of a SARS‐CoV‐2 infection, developing COVID‐19, and having a poor outcome. Still, we believe that standard therapy should be maintained when there is curative intention or when high palliative efficacy has been shown. When faced with two options of similar efficacy, however, the one associated with a lesser risk of infection (i.e. fewer hospital visits, lower levels of myelosuppression) is preferable.

Thus, the aim of this article is to put forward a set of general and specific guidelines to be considered in the context of our national health care system in addition to individualized evaluations regarding BC treatment and patient management. These guidelines may also be applicable to similar health care systems abroad, or they may complement those developed with different health systems in mind [3].

---

### Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19 [^f9015c72]. JCO Global Oncology (2021). Medium credibility.

To our knowledge, this is the largest Latin American cohort to assess the characteristics, determinants of mortality, and clinical outcomes of hospitalized patients with cancer who were diagnosed with COVID-19. Among the limitations of our study, the retrospective nature and the accrual in a single public institution may limit the generalization of our findings. Finally, restricted numbers of specific malignancy types limit our ability to accurately address the influences of individual cancer types and systemic therapeutic regimens on clinical outcomes.

In conclusion, delivering care for patients with cancer during the COVID-19 pandemic has become a major challenge for the cancer care community. Our data demonstrate a high mortality rate in patients with cancer who were diagnosed with COVID-19, emphasizing the need for close surveillance in this group of patients, and provide evidence on determinants of unfavorable outcomes in hospitalized patients with cancer.

---

### Acetylcysteine solution (acetylcysteine) [^2ee807b1]. FDA (2019). Medium credibility.

CONTRAINDICATIONS

Acetylcysteine is contraindicated in those patients who are sensitive to it.

---

### Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19 [^cfd367c4]. JCO Global Oncology (2021). Medium credibility.

INTRODUCTION

From a local epidemic of respiratory disease initially described in the Chinese province of Wuhan, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 emerged as a pandemic that has transformed health care delivery around the globe.Early reports already indicated that the risk of morbidity and mortality from COVID-19 was not uniform across infected patients but was rather dependent on patients' characteristics such as age and comorbidities.Thus, concerns about the risk of unfavorable outcomes in patients with cancer, because of immunosuppression from the disease and antineoplastic therapies,were raised by initial studies reporting higher mortality rates in this population.

Clinicians involved in cancer treatment are faced with potentially competing risks of complications from cancer progression and from COVID-19. Data regarding the interaction between these conditions, critical to inform clinical practice, are still scarce and, often, conflicting. -

Brazil is one of the most affected countries, currently accumulating more than eight million confirmed cases and more than 200,000 deaths.Thus, greater knowledge of local data regarding the COVID-19 outbreak is of utmost importance for the management of patients with cancer.Therefore, the present study evaluates the clinical characteristics, outcomes, and determinants of mortality in a high-risk group of patients with cancer who were infected with SARS-Cov-2.

---

### NCCN guidelines® insights: breast cancer, version 5.2025 [^94635ead]. Journal of the National Comprehensive Cancer Network (2025). High credibility.

Clinical prognostic stage (Table 3) note—the prognostic value of these Prognostic Stage Groups is based on populations of persons with breast cancer that have been offered and mostly treated with appropriate endocrine and/or systemic chemotherapy, including anti-HER2 therapy.

---

### Sodium chloride (nacellate solution 0.9%-100mL) [^74ad9d14]. FDA (2022). Medium credibility.

CONTRAINDICATIONS

This solution is contraindicated where the administration of sodium or chloride could be clinically detrimental.

---

### Acetylcysteine (Acetadote) [^4364bb89]. FDA (2025). Medium credibility.

4 CONTRAINDICATIONS

ACETADOTE is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see Warnings and Precautions (5.1)] .

Patients with a previous hypersensitivity reaction to acetylcysteine (4)

---

### Participación de los pacientes en una intervención de coaching en Línea para padres de niños con retraso en el desarrollo [^c03d55a1]. Developmental Medicine and Child Neurology (2021). Medium credibility.

Objetivo

Evaluar los procesos de participación de los pacientes en el desarrollo de una nueva intervención de coaching de salud para padres de niños con problemas de desarrollo emergentes. MÉTODO: Se utilizó un diseño de estudio transversal de método mixto. Los investigadores (n=18) y los padres-asesores (n=9) fueron encuestados utilizando la Herramienta de Evaluación del Compromiso Público y del Paciente (PPEET) en áreas de comunicación/apoyos para la participación, compartiendo puntos de vista/perspectivas, impactos/influencia de la iniciativa de compromiso, y pensamientos finales/satisfacción. Se utilizaron estadísticas descriptivas y resúmenes temáticos para analizar los datos.

Resultados

Para ambos grupos de estudio, en las cuatro secciones de la PPEET se observó un alto grado de acuerdo, con respuestas que variaban en gran medida entre 'estoy de acuerdo' y 'estoy muy de acuerdo'. Los informes cualitativos reflejaban que la participación de los pacientes era importante, significativa y tenía un impacto significativo en la calidad del proyecto y en el desarrollo profesional de los investigadores en su comprensión y uso de la metodología orientada al paciente. Los padres-asesores señalaron los problemas relacionados con la fijación de plazos realistas para proporcionar la retroalimentación y la falta de una representación más amplia entre los miembros. INTERPRETACIÓN: Se destacaron los beneficios y desafíos de aplicar estrategias orientadas al paciente a un ensayo multicéntrico. Estos se utilizarán para mejorar nuestros procesos de participación.

---

### First-line therapies foreradication: a critical reappraisal of updated guidelines [^0724e03f]. Annals of Gastroenterology (2017). Low credibility.

Table 1 
First-line therapies recommended in Eastern guidelines

Table 2 
First-line therapy recommended in Western guidelines

Table 3 
Eradication rate following 14-day triple therapies in Italy

---

### Work ability in patients with stage I to IV colon cancer: results of the Dutch prospective colorectal cancer cohort [^8533a9e3]. Diseases of the Colon and Rectum (2023). Medium credibility.

Background

Colon cancer affects a patient's ability to work. Many patients who have colon cancer are employed at the time of diagnosis.

Objective

We evaluated work ability during the first 2 years after colon cancer diagnosis.

Design

This study is a national prospective study, the Prospective Dutch ColoRectal Cancer cohort, including clinical data and patient-reported outcomes.

Settings

Data were collected in 59 medical centers in the Netherlands.

Patients

Patients <67 years of age with stage I to IV colon cancer and who completed Work Ability Index questionnaires were selected.

Main Outcome Measures

Work ability was assessed at baseline, 3, 6, 12, 18, and 24 months. The Work Ability Index (range, 0 to 49) was evaluated using linear mixed models. Outcomes were matched to population controls without cancer.

Results

Of 390 patients, 84% had paid employment. Work ability of patients with stage I to IV colon cancer was significantly lower at the time of diagnosis than in matched population controls (31 ± 8.2 and 41 ± 5.6). Patients with stage I to III disease receiving surgery only regained Work Ability Index scores comparable to matched population controls at 18 months. Patients receiving adjuvant systemic treatment initially demonstrated a decrease in work ability with improvements from 6 months onward and normalization at 24 months. Patients with stage IV disease did not demonstrate improvements in work ability outcomes over time. Work ability scores were negatively influenced by the administration of systemic treatment and ≥1 comorbidities.

Limitations

Only patients with patient-reported outcomes and work at baseline were included in this analysis. Also, questionnaire response rates decreased over time.

Conclusions

Work ability in patients with colon cancer is decreased for a prolonged time. Recovery depends on disease stage, type of treatment, and comorbidities. Patients with stage I to III disease treated with curative surgery alone were the first to regain work ability, followed by patients who receive adjuvant chemotherapy. Patients with stage IV disease did not regain work ability. See Video Abstract at http://links.lww.com/DCR/B759 .

Capacidad Laboral En Pacientes Con Cncer De Colon En Estadio Iiv Resultados Prospectivos De Cncer Colorectal En Una Cohorte Holandesa

ANTECEDENTES:El cáncer de colon afecta la capacidad de trabajo en un paciente. Muchos pacientes con cáncer de colon están empleados en el momento del diagnóstico.OBJETIVO:Evaluamos la capacidad laboral durante los dos primeros años posteriores al diagnóstico de cáncer de colon.DISEÑO:Es un estudio prospectivo nacional, la cohorte de cáncer colorrectal holandés, incluye datos clínicos y resultados informados por los pacientes.ENTORNO CLINICO:Se recopilaron datos de 59 centros médicos en los Países Bajos.PACIENTES:Se seleccionaron pacientes < 67 años, con cáncer de colon en estadio I-IV, que completaron los cuestionarios de índice de capacidad para el trabajo.PRINCIPALES MEDIDAS DE VALORACIÓN:La capacidad para el trabajo se evaluó al inicio, a los 3, 6, 12, 18 y 24 meses. El índice de capacidad para el trabajo (que va de 0 a 49) se evaluó mediante modelos lineales mixtos. Los resultados fueron comparados con el grupo control sin cáncer.RESULTADOS:De 390 pacientes, el 84% tenía un empleo remunerado. La capacidad de trabajo de los pacientes en estadio I-IV fue significativamente menor en el momento del diagnóstico en comparación con el grupo control (31 ± 8,2 y 41 ± 5,6, respectivamente). Los pacientes con enfermedad en estadio I-III que recibieron cirugía lograron recuperar puntajes del índice de capacidad laboral comparables a los controles a los 18 meses. Los pacientes que recibieron tratamiento sistémico adyuvante inicialmente demostraron una disminución en la capacidad de trabajo con mejoras a partir de los 6 meses en adelante y una normalización a los 24 meses. Los pacientes en estadio IV no demostraron mejoras en los resultados de la capacidad laboral a lo largo del tiempo. Las puntuaciones de capacidad para el trabajo se vieron influidas negativamente por la administración del tratamiento sistémico y la existencia de ≥1 comorbilidades.LIMITACIONES:En este análisis solo se incluyeron los pacientes con resultados y trabajo desde el inicio del estudio. Además, las tasas de respuesta al cuestionario disminuyeron con el tiempo.CONCLUSIONES:La capacidad de trabajo en pacientes con cáncer de colon se reduce durante un tiempo prolongado. La recuperación depende del estadio de la enfermedad, el tipo de tratamiento y la comorbilidad. Los pacientes con enfermedad en estadio I-III tratados con cirugía curativa exclusivamente, son los primeros en recuperar la capacidad para trabajar, seguidos de los pacientes que reciben quimioterapia adyuvante. Los pacientes con enfermedad en estadio IV no recuperan la capacidad para trabajar. Consulte Video Resumen en http://links.lww.com/DCR/B759 . (Traducción- Dr. Ingrid Melo ).

---

### Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^e98083ea]. Annals of Oncology (2024). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer, adjuvant systemic therapy, HER2+, ESMO 2024 guidelines recommend to offer HER2-directed therapy (with initial concurrent chemotherapy) for 12 months, covering both the neoadjuvant and/or adjuvant phases of treatment.

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^0f7dee4a]. The Oncologist (2020). Medium credibility.

Systemic Therapies for Early Stages

During the administration of chemotherapy and afterward, patients should minimize infection risks by following safety recommendations even more strictly.

To reduce the risk of SARS‐CoV‐2 infection, physicians may choose well‐accepted shorter chemotherapy regimens with lower myelosuppression risk and administered every 3 weeks. In addition, the administration of prophylactic colony‐stimulating factor (CSF) is highly recommended. However, the reduction of chemotherapy dosage to decrease myelosuppression risk is highly discouraged.

---

### Difference in the prognostic benefit between extended and segmental colectomy for patients with neoplasia associated with ulcerative colitis: a nationwide multicenter study [^cb124f3d]. Diseases of the Colon and Rectum (2025). Medium credibility.

Background

Extended colectomy is considered a standard treatment for neoplasia associated with ulcerative colitis, but there is limited supporting evidence, particularly from large-scale studies.

Objective

This study aimed to assess the prognostic benefits of extended colectomy in patients with neoplasia associated with ulcerative colitis using a nationwide database.

Design

Multicenter retrospective study.

Settings

Forty-three institutions in Japan participated in this study.

Patients

The medical records of patients with ulcerative colitis and diagnosed intestinal neoplasia between 1983 and 2020 at 43 institutions were analyzed.

Main Outcome Measures

Five-year overall survival and disease-free survival were assessed on the basis of different surgical procedures, with a subgroup analysis comparing neoplasia associated with ulcerative colitis to sporadic cancer.

Results

Among 879 patients, 801 were diagnosed with neoplasia associated with ulcerative colitis and 78 with sporadic cancer. The 5-year disease-free survival for total proctocolectomy and subtotal colectomy were similar (87.8% and 83.9%), and both were superior to segmental colectomy (72.0%). When comparing neoplasia associated with ulcerative colitis to sporadic cancer, extended colectomy (total proctocolectomy and subtotal colectomy) showed significantly better outcomes for neoplasia associated with ulcerative colitis, whereas no significant difference was observed for sporadic cancer. Multivariable analysis revealed a significantly better prognosis for extended colectomy compared to segmental colectomy in neoplasia associated with patients with ulcerative colitis, both in overall survival and disease-free survival ( p < 0.001).

Limitation

Nonrandomized retrospective study design.

Conclusions

This nationwide cohort study supports extended colectomy as the criterion standard for neoplasia associated with ulcerative colitis management and underscores the importance of accurate diagnosis to distinguish between neoplasia associated with ulcerative colitis and sporadic cancer for optimal treatment decisions. See Video Abstract.

Diferencia En El Beneficio Pronstico Entre La Colectoma Extendida Y Segmentaria Para Pacientes Con Neoplasia Asociada A Colitis Ulcerativa Un Estudio Multicntrico A Nivel Nacional

ANTECEDENTES:La colectomía extendida se considera el tratamiento estándar para la neoplasia asociada con la colitis ulcerativa, pero hay evidencia de respaldo limitada, particularmente de estudios a gran escala.OBJETIVO:Este estudio tuvo como objetivo evaluar los beneficios pronósticos de la colectomía extendida en pacientes con neoplasia asociada con colitis ulcerativa utilizando una base de datos nacional.DISEÑO:Estudio retrospectivo multicéntrico.ESCENARIO:Cuarenta y tres instituciones en Japón participaron en este estudio.PACIENTES:Se analizaron pacientes con colitis ulcerativa diagnosticados con neoplasia intestinal entre 1983 y 2020 en 43 instituciones.PRINCIPALES MEDIDAS DE RESULTADOS:Se evaluaron la supervivencia general a cinco años y la supervivencia libre de enfermedad en función de diferentes procedimientos quirúrgicos, con un análisis de subgrupos que comparaba la neoplasia asociada con colitis ulcerativa con el cáncer esporádico.RESULTADOS:Entre 879 pacientes, 801 fueron diagnosticados con neoplasia asociada con colitis ulcerativa y 78 con cáncer esporádico. La supervivencia libre de enfermedad a 5 años para la proctocolectomía total y la colectomía subtotal fue similar (87,8% y 83,9%), ambas superiores a la colectomía segmentaria (72,0%). Al comparar la neoplasia asociada a la colitis ulcerativa con el cáncer esporádico, la colectomía extendida (proctocolectomía total y colectomía subtotal) mostró resultados significativamente mejores para la neoplasia asociada a la colitis ulcerativa, mientras que no se observó una diferencia significativa para el cáncer esporádico. El análisis multivariable reveló un pronóstico significativamente mejor para la colectomía extendida en comparación con la colectomía segmentaria en pacientes con neoplasia asociada a la colitis ulcerativa, tanto en la supervivencia general como en la supervivencia libre de enfermedad (p < 0,001).LIMITACIÓN:Diseño de estudio retrospectivo no aleatorizado.CONCLUSIÓN:Este estudio de cohorte a nivel nacional respalda la colectomía extendida como el estándar de oro para el manejo de la neoplasia asociada a la colitis ulcerativa y subraya la importancia de un diagnóstico preciso para distinguir entre la neoplasia asociada a la colitis ulcerativa y el cáncer esporádico para tomar decisiones óptimas de tratamiento. (Traducción- Dr. Francisco M. Abarca-Rendon ).

---

### Multimodal endoscopic assessment guides treatment decisions for rectal early neoplastic tumors [^0ec4a783]. Diseases of the Colon and Rectum (2020). Medium credibility.

Background

There is a trend toward organ conservation in the management of rectal tumors. However, there is no consensus on standardized investigations to guide treatment.

Objective

We report the value of multimodal endoscopic assessment (white light, magnification chromoendoscopy and narrow band imaging, selected colonoscopic ultrasound) for rectal early neoplastic tumors to inform treatment decisions.

Design

This was a retrospective study.

Setting

The study was conducted in a tertiary referral unit for interventional endoscopy and early colorectal cancer.

Patients

A total of 296 patients referred with rectal early neoplastic tumors were assessed using standardized multimodal endoscopic assessment and classified according to risk of harboring invasive cancer.

Main Outcome Measures

Sensitivity, specificity, positive and negative predictive values of multimodal endoscopic assessment, and previous biopsy to predict invasive cancer were calculated and treatment outcomes reported.

Results

After multimodal endoscopic assessment, lesions were classified as invasive cancer, at least deep submucosal invasion (n = 65); invasive cancer, superficial submucosal invasion or high risk of covert cancer (n = 119); or low risk of covert cancer (n = 112). Sensitivity, specificity, positive predictive values, and negative predictive values of multimodal endoscopic assessment for diagnosing invasive cancer, deep submucosal invasion, were 77%, 98%, 93%, and 93%. The combined classification of all lesions with invasive cancer or high risk of covert cancer had a negative predictive value of 96% for invasive cancer on final histopathology. Sensitivity of previous biopsy was 37%. A total of 47 patients underwent radical surgery and 33 transanal endoscopic microsurgery. No patients without invasive cancer were subjected to radical surgery; 222 patients initially underwent endoscopic resection. Of the 203 without deep submucosal invasion, 95% avoided surgery and were free from recurrence at last follow-up.

Limitations

This was a retrospective study from a tertiary referral unit.

Conclusions

Standardized multimodal endoscopic assessment guides rational treatment decisions for rectal tumors resulting in organ-conserving treatment for all patients without deep submucosal invasive cancer. See Video Abstract at http://links.lww.com/DCR/B133. LA EVALUACIÓN ENDOSCÓPICA MULTIMODAL COMO GUÍA DE DECISIONES EN EL TRATAMIENTO DE TUMORES RECTALES NEOPLÁSICOS PRECOCES: La tendencia actual es la preservación del órgano en el manejo de los tumores de rectao. Sin embargo, no hay consenso sobre las investigaciones estandar para guiar dicho tratamiento.Presentamos los valores de la evaluación endoscópica multimodal (luz blanca, cromoendoscopia de aumento, imagen de banda estrecha y ecografía colonoscópica seleccionada) para tumores rectales neoplásicos tempranos y así notificar las decisiones sobre el tratamiento.Estudio retrospectivo.El estudio se realizó en una unidad de referencia terciaria para endoscopia intervencionista y cáncer colorrectal temprano.Se evaluaron 296 pacientes referidos con tumores neoplásicos precoces de recto mediante una evaluación endoscópica multimodal estandarizada y se clasificaron de acuerdo al riesgo de albergar un cáncer invasivo.Se calcularon la sensibilidad, la especificidad, los valores predictivos positivos y negativos de la evaluación endoscópica multimodal y la biopsia previa para predecir el cáncer invasivo y se notificaron los resultados para el tratamiento.Después de la evaluación endoscópica multimodal, las lesiones se clasificaron como: cáncer invasive (al menos invasión submucosa profunda n = 65); cáncer invasive (invasión submucosa superficial o alto riesgo de cáncer encubierto n = 119) y finalmente aquellos de bajo riesgo de cáncer encubierto (n = 112). La sensibilidad, la especificidad, los valores predictivos positivos y negativos de la evaluación endoscópica multimodal para el diagnóstico de cáncer invasivo, la invasión submucosa profunda fueron 77%, 98%, 93% y 93% respectivamente. La clasificación combinada de todas las lesiones con cáncer invasivo o de alto riesgo de cáncer encubierto tuvo un VPN del 96% para el cáncer invasivo en la histopatología final. La sensibilidad fué de 37% en todas las biopsias previas. 47 pacientes fueron sometidos a cirugía radical, 33 por microcirugía endoscópica transanal. Ningún paciente sin cáncer invasivo fue sometido a cirugía radical. Inicialmente, 222 pacientes fueron sometidos a resección endoscópica. De los 203 sin invasión submucosa profunda, el 95% evitó la cirugía y no tuvieron recurrencia en el último seguimiento.Estudio retrospectivo de una unidad de referencia terciaria.La evaluación endoscópica multimodal estandarizada guía las decisiones racionales de tratamiento para los tumores rectales que resultan en un tratamiento conservador de órganos para todos los pacientes sin cáncer invasivo submucoso profundo. Consulte Video Resumen en http://links.lww.com/DCR/B133.

---

### Solucion aditiva para plaquetas 3 (solucion interSol) [^fd105d94]. FDA (2021). Medium credibility.

 Estudio de eventos adversos (EA) relacionados con la transfusión después de que el producto ha salido al mercado 

Se realizó en 6 instituciones un estudio retrospectivo a etiqueta abierta y no aleatorio de revisión de registros médicos a fin de demostrar que el índice global de EA relacionados con la transfusión en pacientes que reciben transfusiones de plaquetas con InterSol no fue mayor que el doble del índice observado en pacientes que recibieron plaquetas de aféresis almacenadas en plasma al 100% (plaquetas con plasma). El estudio clasificó las reacciones adversas a la transfusión según las definiciones descritas por “Biovigilance Component” del sistema “National Healthcare Safety Network” (NHSN). A todas las instituciones participantes se les exigió tener sistemas instalados para la observación de EA relacionados con la transfusión y para registrar cuando lo observado no era ningún EA relacionado con la transfusión. Un comité independiente de casos clínicos (CEC, Clinical Events Committee), sin ningún conocimiento del tipo de plaquetas y de la institución donde se realizó el estudio, se encargó de adjudicar los eventos registrados.

---

### Antibiotic strategies in the era of multidrug resistance [^044c473c]. Critical Care (2016). Low credibility.

Background

ICU patients are particularly at risk of developing infections with multidrug-resistant (MDR) organisms, which are more prevalent in this environment. Appropriate and adequate antibiotic coverage is essential in the treatment of these patients. In the present update, we will discuss the mechanisms of development of resistance, before highlighting some of the key issues related to antibiotic management and possible approaches to prevent further development of resistance.

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^16730a11]. The Oncologist (2020). Medium credibility.

Testing Patients for‐2

Patients with cancer on active or recently finished (≤3 months) myelosuppressive therapy are more susceptible to infections as compared with individuals without cancer. Once diagnosed with COVID‐19, they are at a higher risk of severe events (i.e. need for invasive ventilation or death) and quick deterioration [2]. In a scenario in which four out of five infected patients might be asymptomatic [31], our recommendation is that all patients in need of any major surgery or invasive medical procedure with involvement of the respiratory tract (e.g. bronchoscopy) or sedation (e.g. gastrointestinal surgery, endoscopy) and starting or resuming myelosuppressive therapy should be first tested for SARS‐CoV‐2 regardless of their symptoms or contact history with infected individuals. In case of a shortage of tests available, high‐risk patients (e.g. older age, obesity, diabetes, chronic obstructive pulmonary disease, hepatopathy, nephropathy, cardiopathy, heavy smokers) should be prioritized for testing.

Patients positive for SARS‐CoV‐2 should have their myelosuppressive treatment delayed until they test negative. If testing is not available, the patient should be symptom free for at least 2 weeks before weighing with the physician the risk/benefit ratio of resuming treatment.

Patients presenting symptoms suggestive of infection such as fever, dry cough, dyspnea, anosmia, ageusia, myalgia, and gastrointestinal symptoms (nausea, vomiting, or diarrhea) should also postpone treatment even if they test negative for the virus.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^e28d7bdf]. Developmental Medicine and Child Neurology (2025). Medium credibility.

Enfoque para evaluar generalización y transferencia

La generalización más allá de las tareas entrenadas y la transferencia se ha informado en una revisión de alcance recienteque contiene estudios incluidos en la revisión de alcance anterior (con una pregunta de investigación diferente).La evidencia de transferencia se midió utilizando cuatro indicadores diferentes que incluyen (1) Transferencia a objetivos no trabajados durante CO‐OP; (2) puntuaciones de otras evaluaciones estandarizadas de actividades, habilidades o componentes del desempeño ; (3) puntuaciones de resultados validados reportados por pacientes; y (4) informes anecdóticos. La mayoría de los estudios abordaron la transferencia (n = 25), con 16 evaluando la transferencia explícitamente y nueve abordando la transferencia con uno de los indicadores mencionados anteriormente. Los autores de la revisión destacan la variabilidad en los enfoques para medir la transferencia y las medidas y definiciones utilizadas, lo que limita la comparación entre estudios.

---

### Socioeconomic disparities in anal cancer: effect on treatment delay and survival [^496bef7d]. Diseases of the Colon and Rectum (2024). Medium credibility.

Background

Socioeconomic inequities have implications for access to health care and may be associated with disparities in treatment and survival.

Objective

To investigate the impact of socioeconomic inequities on time to treatment and survival of anal squamous-cell carcinoma.

Design

This is a retrospective study using a nationwide data set.

Settings

The patients were selected from the National Cancer Database and enrolled from 2004 to 2016.

Patients

We identified patients with stage I to III squamous-cell carcinoma of the anus who were treated with chemoradiation therapy.

Main Outcomes Measures

Socioeconomic factors, including race, insurance status, median household income, and percentage of the population with no high school degrees, were included. The association of these factors with treatment delay and overall survival was investigated.

Results

A total of 24,143 patients who underwent treatment for grade I to III squamous-cell carcinoma of the anus were identified. The median age was 60 years, and 70% of patients were women. The median time to initiation of treatment was 33 days. Patients from zip codes with lower median income, patients with a higher percentage of no high school degree, and patients with other government insurance followed by Medicaid insurance had treatment initiated after 60 days from diagnosis. Kaplan-Meier survival analysis showed that the late-treatment group had worse overall survival compared to the early treatment group (98 vs 125 months; p < 0.001).

Limitations

No detailed information is available about the chemoradiotherapy regimen, completion of treatment, recurrence, disease-free survival, and individual-level socioeconomic condition and risk factors.

Conclusion

Patients from communities with lower median income, level of education, and enrolled in public insurance had longer time to treatment. Lower socioeconomic status was also associated with poorer overall survival. These results warrant further analysis and measures to improve access to care to address this disparity. See Video Abstract .

Desigualdades Socioeconmicas En Casos De Cncer Anal Efectos En El Retraso Del Tratamiento Y La Sobrevida

ANTECEDENTES:Las desigualdades socio-económicas tienen implicaciones en el acceso a la atención médica y pueden estar asociadas con disparidades en el tratamiento y la sobrevida.OBJETIVO:Indagar el impacto de las desigualdades socio-económicas sobre el tiempo de retraso en el tratamiento y la sobrevida en casos de carcinoma a células escamosas del ano (CCEA).DISEÑO:Estudio retrospectivo utilizando un conjunto de datos a nivel nacional.AJUSTES:Todos aquellos pacientes inscritos entre 2004 a 2016 y que fueron seleccionados de la Base Nacional de Datos sobre el Cáncer.PACIENTES:Identificamos pacientes con CCEA en estadíos I-III y que fueron tratados con radio-quimioterápia.PRINCIPALES MEDIDAS DE RESULTADOS:Se incluyeron factores socio-económicos tales como la raza, el tipo de seguro de salud, el ingreso familiar medio y el porcentaje de personas sin bachillerato de secundaria (SBS). Se investigó la asociación entre estos factores con el retraso en iniciar el tratamiento y la sobrevida global.RESULTADOS:Se identificaron un total de 24.143 pacientes que recibieron tratamiento para CCEA estadíos I-III. La mediana de edad fue de 60 años donde 70% eran de sexo femenino. La mediana del tiempo transcurrido desde el diagnóstico hasta el inicio del tratamiento fue de 33 días. Los pacientes residentes en zonas de código postal con ingresos medios más bajos, con un mayor porcentaje de individuos SBS y los pacientes con otro tipo de seguro gubernamental de salud, seguidos del seguro tipo Medicaid iniciaron el tratamiento solamente después de 60 días al diagnóstico inicial de CCEA. El análisis de Kaplan-Meier de la sobrevida mostró que el grupo de tratamiento tardío tuvo una peor supervivencia general comparada con el grupo de tratamiento precoz o temprano (98 frente a 125 meses; p <0,001).LIMITACIONES:No se dispone de información detallada sobre el tipo de radio-quimioterapia utilizada, ni sobre la finalización del tratamiento o la recurrencia, tampoco acerca de la sobrevida libre de enfermedad ni sobre las condiciones socio-económicas o aquellos factores de riesgo a nivel individual.CONCLUSIÓN:Los pacientes de comunidades con ingresos medios más bajos, con un nivel de educación limitado e inscritos en un seguro público tardaron mucho más tiempo en recibir el tratamiento prescrito. El nivel socio-económico más bajo también se asoció con una sobrevida global más baja. Los presentes resultados justifican mayor análisis y medidas mas importantes para mejorar el acceso a la atención en salud y poder afrontar esta disparidad. (Traducción-Dr. Xavier Delgadillo ).

---

### Symptomatic treatment of cough among adult patients with lung cancer: CHEST guideline and expert panel report [^a7eafc89]. Chest (2017). Medium credibility.

Advanced NSCLC radiotherapy—comparative trial outcomes: In a comparative trial of advanced NSCLC (N = 320), all patients received 2 Gy per fraction for up to 50 Gy in three groups, with similar response in all three groups.

---

### Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion [^9de16f5f]. Fertility and Sterility (2023). High credibility.

ASRM Pages—evaluación diagnóstica de la disfunción sexual en la pareja masculina en el contexto de la infertilidad—states that “Es responsabilidad del médico evaluar la presencia de disfunción eréctil, disfunción eyaculatoria o disminución de la libido en hombres que se presentan para la evaluación de infertilidad,” and advises that “A menudo se justifica la derivación a un urólogo reproductivo u otro especialista apropiado con la experiencia necesaria en la evaluación y el tratamiento de estas condiciones, incluido el tratamiento adecuado de la deficiencia de testosterona”; it further notes, “Este artículo reemplaza el artículo del mismo nombre, publicado por última vez en 2018.”

---

### Maintaining breast cancer care in the face of COVID-19 [^e1750ed4]. The British Journal of Surgery (2020). Medium credibility.

The battle of COVID-19 is currently at different levels of intensity in each country and even each city. The authors have prepared succinct recommendations regarding the care of patients with breast cancer, divided into phases that can easily be adapted to each units' needs and resources, and stepped up or stepped down according to escalating and de-escalating circumstances. The structure can also be transposed easily to different cancer types, enabling continued provision of best standards of care despite unprecedented stressors. Surgery must go on.

---

### Impact of COVID-19 infection on patients with cancer: experience in a latin American country: the ACHOCC-19 study [^ae8b77e6]. The Oncologist (2021). Medium credibility.

Results

Of the 783 patients collected in the ACHOCC‐19, 41 patients were excluded because of duplication of information. All records were started during the COVID‐19 pandemic and 100% had a 30‐day follow‐up report (interquartile range, 0–30 days).

Regarding the demographic, clinical, tumor, and socioeconomic characteristics of the population (Table 1), 534 (72%) patients were older than 51 years and 200 (27%) older than 70 years. Four hundred three (54%) were women. As risk factors for complications from COVID‐19, 18 (2.42%) had active smoking, 87 (11.7%) had more than two comorbidities, 37 (14%) had an ECOG performance status >2, and 295 (38.7%) had metastatic neoplasia.

Table 1 
Description of the population characteristics

The area of residence was urban for 677 (91%) patients and 354 (47.7%) belonged to the low‐income socioeconomic level. The most prevalent neoplasms were breast cancer (n = 132, 17.77%), colorectal cancer (n = 92, 12.34%), and prostate cancer (n = 81, 10.9%).

Regarding cancer treatment, 352 (63.9%) patients were in active treatment, of whom 213 (28.67%) received systemic treatment with palliative intention. Eighty‐one patients (10.98%) had undergone surgical treatment in the month prior to COVID‐19 infection.

Of those who were receiving active cancer treatment, 205 (27.6%) had a partial response or stable disease and 147 (36.38%) had progressing cancer. A total of 454 (61.18%) patients had received cancer therapy within the previous 12 months. According to the type of treatment, 209 (28.18%) were receiving cytotoxic therapy and 144 (19.5%) were under noncytotoxic treatment.

---

### Clinical validity of tumor-informed circulating tumor DNA analysis in patients undergoing surgery of colorectal metastases [^f607cab1]. Diseases of the Colon and Rectum (2023). Medium credibility.

BACKGROUND:

Accurate biomarkers to monitor tumor load and response in metastatic colorectal cancer patients undergoing surgery could optimize treatment regimens.

OBJECTIVE:

This study aimed to explore the clinical validity of tumor-informed quantification of circulating tumor DNA in blood using ultradeep sequencing.

DESIGN:

Resection specimens from 53 colorectal cancer patients were analyzed for tumor-specific mutations in 15 genes. These mutations were used to measure the presence of circulating tumor DNA in preoperatively collected plasma samples using hybrid capture-based sequencing. Additional postoperative measurements were performed 1 week after surgery in 16 patients.

SETTINGS:

The study was conducted at the Radboud University Medical Center.

PATIENTS:

A total of 53 colorectal cancer patients undergoing surgery of metastases were included.

MAIN OUTCOME MEASURES:

The detection of circulating tumor DNA.

RESULTS:

At least 1 tumor-specific mutation was detected in all tumor samples. In preoperative plasma samples, circulating tumor DNA was detected in 88% (37/42) of systemic treatment-naïve patients and in 55% (6/11) of patients who received preoperative chemotherapy. More specifically, circulating tumor DNA was detected in 0% (0/3) of cases with a subtotal or partial pathologic response and in 75% (6/8) of cases without a pathologic response in the resection specimen (p = 0.06). In postoperative plasma samples, circulating tumor DNA was detected in 80% (4/5) of patients with an incomplete resection and in 0% (0/11) of those with a complete resection (p = 0.003).

LIMITATIONS:

The study was limited by the heterogeneity of the cohort and the small number of postoperative plasma samples.

CONCLUSIONS:

These data indicate that tumor-informed circulating tumor DNA detection in the plasma of patients undergoing surgery for metastatic colorectal cancer is feasible and may have clinical value in response monitoring and predicting residual disease. Prospective studies are needed to establish the clinical utility of circulating tumor DNA analysis to guide treatment decisions in these patients. See Video Abstract at.

VALIDEZ CLÍNICA DEL ANÁLISIS DE ADN DEL TUMOR CIRCULANTE INFORMADO POR EL TUMOR EN PACIENTES SOMETIDOS A CIRUGÍA DE METÁSTASIS COLORRECTALES

ANTECEDENTES:

Los biomarcadores precisos para monitorear la carga tumoral y la respuesta en pacientes con cáncer colorrectal metastásico que se someten a cirugía podrían optimizar los regímenes de tratamiento.

OBJETIVO:

Este estudio explora la validez clínica de la cuantificación informada por el tumor del ADN tumoral circulante en sangre mediante secuenciación ultraprofunda.

DISEÑO:

Se analizaron muestras de resección de 53 pacientes con cáncer colorrectal en busca de mutaciones específicas del tumor en quince genes. Estas mutaciones se usaron para medir la presencia de ADN tumoral circulante en muestras de plasma recolectadas antes de la operación usando secuenciación basada en captura híbrida. Se realizaron mediciones postoperatorias adicionales una semana después de la cirugía en dieciséis pacientes.

AJUSTES:

El estudio se realizó en el centro médico de la universidad de Radboud.

PACIENTES:

Se incluyeron un total de 53 pacientes con cáncer colorrectal sometidos a cirugía de metástasis.

PRINCIPALES MEDIDAS DE RESULTADO:

La detección de ADN tumoral circulante.

RESULTADOS:

Se detectó al menos una mutación específica de tumor en todas las muestras de tumor. En muestras de plasma preoperatorias, se detectó ADN tumoral circulante en el 88% (37/42) de los pacientes sin tratamiento sistémico previo y en el 55% (6/11) de los pacientes que recibieron quimioterapia preoperatoria. Más concretamente, en el 0% (0/3) de los casos con respuesta patológica subtotal o parcial y en el 75% (6/8) de los casos sin respuesta patológica en la pieza de resección (p = 0,06). En muestras de plasma postoperatorio se detectó ADN tumoral circulante en el 80% (4/5) de los pacientes con una resección incompleta y en el 0% (0/11) de los que tenían resección completa (p = 0,003).

LIMITACIONES:

El estudio estuvo limitado por la heterogeneidad de la cohorte y el pequeño número de muestras de plasma postoperatorias.

CONCLUSIONES:

Estos datos indican que la detección de ADN tumoral circulante informado por el tumor en el plasma de pacientes sometidos a cirugía por cáncer colorrectal metastásico es factible y puede tener valor clínico en el control de la respuesta y la predicción de la enfermedad residual. Se necesitan estudios prospectivos para establecer la utilidad clínica del análisis de ADN tumoral circulante para guiar las decisiones de tratamiento en estos pacientes. Consulte Video Resumen en. (Traducción—Dr. Mauricio Santamaria)

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^394971f0]. The Oncologist (2020). Medium credibility.

Materials and Methods

A multidisciplinary group of cancer experts, working under the umbrella of the GEICAM Spanish Breast Cancer Group, developed the following clinical practice‐ and evidence‐based guidelines. Because of the sudden and unexpected pandemic situation, the evidence related to COVID‐19 infection and its implications in the care of patients with breast cancer is scarce. Thus, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and published evidence. First, we produced a number of general recommendations for patient management but also for hospitals and health care personnel (HCP). Second, we organized specific guidelines by stage of disease and BC subtypes. Third, we described SARS‐CoV‐2 testing procedures and patients to be tested. Finally, we included intensive care unit (ICU) admission criteria relevant to patients with BC.

---

### NCCN guidelines® insights: breast cancer, version 5.2025 [^589e1ff1]. Journal of the National Comprehensive Cancer Network (2025). High credibility.

Adjuvant systemic therapy completion after neoadjuvant treatment: Complete the planned systemic therapy neoadjuvant regimen course if not completed preoperatively.

---

### La FDA aprueba un nuevo tratamiento para la neumonía causada (...) [^639e0984]. FDA (2023). Medium credibility.

- For Immediate Release: Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos aprobó Xacduro, un nuevo tratamiento para la neumonía bacteriana adquirida en el hospital y la neumonía bacteriana asociada al ventilador causada por cepas susceptibles de bacterias llamadas complejo. “La FDA se dedica a respaldar el desarrollo de opciones de tratamiento seguras y eficaces para las infecciones causadas por bacterias difíciles de combatir como el complejo Acinetobacter baumannii-calcoaceticus”, afirmó el doctor Peter Kim, director de la División de Antiinfecciosos en el Centro de Evaluación e Investigación de Medicamentos de la FDA.

“La aprobación de hoy ayuda a abordar una gran necesidad médica desatendida al brindar una opción de tratamiento adicional para algunos de los pacientes más enfermos en los hospitales de nuestra nación”. . La eficacia de Xacduro se estableció en un estudio clínico multicéntrico, controlado con un principio activo, de etiqueta abierta, de no inferioridad en 177 adultos hospitalizados con neumonía causada por. A. baumannii resistente a carbapenem. Los pacientes recibieron Xacduro o colistina hasta por 14 días. Ambos grupos de tratamiento también recibieron un antibiótico adicional, imipenem o cilastatina, como terapia de base para posibles patógenos HABP o VABP aparte del complejo Acinetobacter baumannii-calcoaceticus. La medida principal de eficacia fue la mortalidad por todo tipo de causas en un período de 28 días de tratamiento en pacientes con infección confirmada por A. baumannii resistente a carbapenem.

De los pacientes que recibieron Xacduro, el 19 % murió, en comparación con el 32 % que recibieron colistina. Esto demostró que Xacduro no era inferior a la colistina.

---

### Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline [^9533125e]. Journal of Clinical Oncology (2021). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer, neoadjuvant therapy, HER2+, ASCO 2021 guidelines recommend to offer neoadjuvant systemic therapy in patients with high-risk HER2+ if the finding of residual disease would guide recommendations related to adjuvant therapy.

---

### NCCN guidelines® insights: breast cancer, version 5.2025 [^ef8018d7]. Journal of the National Comprehensive Cancer Network (2025). High credibility.

NCCN Guidelines Version 4.2025 Breast Cancer—preoperative chemotherapy options: A number of chemotherapy regimens have activity in the preoperative setting, and according to the NCCN Panel, those regimens recommended in the adjuvant setting may be considered in the preoperative setting, with the aim in both settings being eradication or control of undiscovered distant metastases.

---

### Daptomycin (Dapzura rt) [^75556dc1]. FDA (2022). Medium credibility.

1.5 Usage

Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DAPZURA RT and other antibacterial drugs, DAPZURA RT should be used only to prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information is available, it should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.

---

### Eribulin mesylate [^ff7acdc8]. FDA (2025). Medium credibility.

14.1 Metastatic Breast Cancer

Study 1 was an open-label, randomized, multicenter trial of 762 patients with metastatic breast cancer who received at least two chemotherapeutic regimens for the treatment of metastatic disease and experienced disease progression within 6 months of their last chemotherapeutic regimen. Patients were required to receive prior anthracycline- and taxane-based chemotherapy for adjuvant or metastatic disease. Patients were randomized (2:1) to receive eribulin mesylate injection (n=508) or a single agent therapy selected prior to randomization (control arm, n=254). Randomization was stratified by geographic region, HER2/ neu status, and prior capecitabine exposure. Eribulin mesylate injection was administered at a dose of 1.4 mg/m2 on Days 1 and 8 of a 21-day cycle. Eribulin mesylate injection -treated patients received a median of 5 cycles (range: 1 to 23 cycles) of therapy.  Control arm therapy consisted of 97% chemotherapy (26% vinorelbine, 18% gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy), and 3% hormonal therapy. The main efficacy outcome was overall survival.

Patient demographic and baseline characteristics were comparable between the treatment arms. The median age was 55 (range: 27 to 85 years) and 92% were White. Sixty-four percent of patients were enrolled in North America/Western Europe/Australia, 25% in Eastern Europe/Russia, and 11% in Latin America/South Africa.  Ninety-one percent of patients had a baseline ECOG performance status of 0 or 1. Tumor prognostic characteristics, including estrogen receptor status (positive: 67%, negative: 28%), progesterone receptor status (positive: 49%, negative: 39%), HER2/ neu receptor status (positive: 16%, negative: 74%), triple negative status (ER-, PR-, HER2/ neu -: 19%), presence of visceral disease (82%, including 60% liver and 38% lung) and bone disease (61%), and number of sites of metastases (greater than two: 50%), were also similar in the eribulin mesylate injection and control arms. Patients received a median of four prior chemotherapy regimens in both arms.

---

### Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline [^086939a8]. Journal of Clinical Oncology (2021). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer (neoadjuvant therapy, general principles), ASCO 2021 guidelines recommend to offer neoadjuvant chemotherapy as the treatment of choice in patients with inflammatory breast cancer or unresectable disease that could potentially become resectable with neoadjuvant therapy.

---

### Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update [^853fc90f]. Journal of Clinical Oncology (2019). High credibility.

Regarding preventative measures for breast cancer, more specifically with respect to chemoprophylaxis, ASCO 2019 guidelines recommend to recognize that women most likely to benefit from endocrine therapy are those with one or more of the following: a diagnosis of atypical (ductal or lobular) hyperplasia or lobular carcinoma in situ, an estimated 5-year risk (National Cancer Institute Breast Cancer Risk Assessment Tool) of at least 3%, a 10-year risk (International Breast Intervention Study/Tyrer-Cuzick Risk Calculator) of at least 5%, or a relative risk of at least four times the population risk for their age group if they are age 40 to 44 years or two times the population risk for their age group if they are age 45 to 69 years.

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^4cdc6d95]. The Oncologist (2020). Medium credibility.

Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. IMPLICATIONS FOR PRACTICE: This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare.

---

### The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018) [^b2e43578]. Diseases of the Colon and Rectum (2018). Medium credibility.

Regarding medical management for anal cancer, more specifically with respect to general principles, ASCRS 2018 guidelines recommend to offer a combination of 5-FU and mitomycin C in conjunction with radiotherapy as first-line multimodal therapy in patients with SCC of the anus.

---

### Second consensus on medical treatment of metastatic breast cancer [^6bd7ea47]. Annals of Oncology (2007). Low credibility.

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

---

### Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^526c0b5b]. Annals of Oncology (2024). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer, neoadjuvant therapy, HER2+, ESMO 2024 guidelines recommend to offer HER2-directed therapy (with initial concurrent chemotherapy) for 12 months, covering both the neoadjuvant and/or adjuvant phases of treatment.

---

### Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 [^31effec2]. Annals of Oncology (2007). Low credibility.

Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

---

### Update on randomized trials on recurrent disease [^9b9c465c]. Annals of Oncology (2013). Low credibility.

Approximately 75% of patients with advanced ovarian cancer will have a recurrence of their disease within the first 3 years after upfront surgery and paclitaxel-carboplatin-based chemotherapy. An optimal choice of treatment of patients with a recurrence is an important issue, and several factors should be taken into account in this decision-making, including disease, patients, and treatment. Fortunately, we have several strategies that can be of help not only with respect to palliation, but also in terms of survival benefit. Apart from surgery, which will be reviewed in another article of this series, different single cytotoxic agents and combinations and, more recently, the addition of antiangiogenic agents have shown that they can have impact on progression-free survival and, for some strategies, on the overall survival in such patients. In this review, we present an update of the clinical trials that have led to these achievements.

---

### Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline [^98bb0185]. JCO Global Oncology (2024). High credibility.

Third-line and beyond systemic metastatic breast cancer—triple-negative: The table lists “Palliativea and best supportive care,” and, in the enhanced column, “Single-agent chemotherapy rather than combination chemotherapy.”

---

### Impact of COVID-19 infection on patients with cancer: experience in a latin American country: the ACHOCC-19 study [^8e2ee1e0]. The Oncologist (2021). Medium credibility.

Introduction

The ACHOCC-19 study was performed to characterize COVID-19 infection in a Colombian oncological population.

Methodology

Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression.

Results

The study included 742 patients; 72% were >51years. The most prevalent neoplasms were breast (132, 17.77%), colorectal (92, 12.34%), and prostate (81, 10.9%). Two hundred twenty (29.6%) patients were asymptomatic and 96 (26.3%) died. In the bivariate descriptive analysis, higher mortality occurred in patients who were >70years, patients with lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute-phase reactants. In the logistic regression analysis, higher mortality was associated with Eastern Cooperative Oncology Group performance status (ECOG PS) 3 (odds ratio [OR] 28.67; 95% confidence interval [CI], 8.2-99.6); ECOG PS 4 (OR 20.89; 95% CI, 3.36-129.7); two complications from COVID-19 (OR 5.3; 95% CI, 1.50-18.1); and cancer in progression (OR 2.08; 95% CI, 1.01-4.27). In the Cox regression analysis, the statistically significant hazard ratios (HR) were metastatic disease (HR 1.58; 95% CI, 1.16-2.16), cancer in progression (HR 1.08; 95% CI, 1.24-2.61) cancer in partial response (HR 0.31; 95% CI, 0.11-0.88), use of steroids (HR 1.44; 95% CI, 1.01-2.06), and use of antibiotics (HR 2.11; 95% CI, 1.47-2.95).

Conclusion

In our study, patients with cancer have higher mortality due to COVID-19 infection if they have active cancer, metastatic or progressive cancer, ECOG PS >2, and low socioeconomic status.

Implications For Practice

This study's findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired Eastern Cooperative Oncology Group status to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment.

---

### Latin American consensus for the evaluation and treatment of patients with metastatic / locally advanced urothelial carcinoma [^9180e885]. JCO Global Oncology (2024). Medium credibility.

RESULTS

General Considerations

The statements made from this consensus are suggested practice recommendations without constituting a limiting care guideline, particularly in the Latin American context, where it is essential to consider therapeutic decisions in light of the realities of the specific clinical setting and the availability of resources.

Managing patients in advanced stages of the oncologic disease can be challenging. Providing clear and comprehensive information to patients about all the possible benefits and side effects of each therapy facilitates shared decision making.

Regardless of the specific regimen used, patients receiving chemotherapy should be reassessed every three to four cycles. Treatment must be continued until disease progression or unacceptable toxicity.

All patients should be referred early to palliative care for simultaneous management, with benefits that include reduction of disease-related symptoms, improvement in functional status, increase in quality of life, and reduction in the use of systemic treatments at the end of life.

---

### Acetylcysteine solution (acetylcysteine) [^d07b17ae]. FDA (2019). Medium credibility.

CONTRAINDICATIONS

There are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

---

### Definitive chemoradiation for rectal cancer: is there a role for dose escalation? A national cancer database study [^933b422f]. Diseases of the Colon and Rectum (2019). Medium credibility.

Background

Surgery remains the standard of care in rectal cancer. Select patients will not undergo surgery for reasons such as medical inoperability or a watch-and-wait approach and instead are managed with definitive chemoradiation.

Objective

We used the National Cancer Database to identify overall survival and predictors thereof in the nonoperative management of patients with rectal cancer.

Design

This was a retrospective review.

Settings

This study used deidentified data from the National Cancer Database.

Patients

We queried the national cancer database from 2004 to 2014 for stage 1 to 3 rectal adenocarcinoma treated with only chemotherapy and radiation to definitive doses. Dose escalated therapy was defined as >54 Gy.

Main Outcome Measures

Univariable and multivariable analyses were performed to identify sociodemographic, treatment, and tumor characteristics predictive of dose escalation and overall survival. Propensity-adjusted Cox proportional hazard ratios for survival were used to account for indication bias.

Results

Among the 6311 patients eligible for the study, 11% were treated with doses >54 Gy. Earlier stage and increased age/comorbidity patients were more likely to receive dose escalation, and patients with more recent treatment and treatment at an academic facility were less likely. The median follow-up time was 31 months (range, 2-154 mo). Three- and 5-year overall survival rates for all patients were 60% and 46%. Patients treated with dose escalation had a median survival of 33 months compared with 56 months for those treated with ≤54 Gy (p < 0.0001).

Limitations

The main limitation is the inherent selection bias present in National Cancer Database studies. Important treatment details and outcomes as they relate to a definitive chemoradiation approach in rectal cancer are lacking. Salvage therapy was also not recorded, which in this population could be surgery.

Conclusions

In this analysis, dose escalation in the nonoperative management of rectal cancer was associated with a lower overall survival compared with more conventional doses. Careful patient selection and enrollment on appropriate clinical trials may be warranted in the nonoperative setting. See Video Abstract at http://links.lww.com/DCR/B15. LA QUIMIORRADIACIÓN DEFINITIVA PARA EL CÁNCER RECTAL: ¿HAY LUGAR PARA EL AUMENTO DE LA DOSIS? UN ESTUDIO DE BASE DE DATOS NACIONAL DEL CÁNCER:: La cirugía sigue siendo el estándar en el tratamiento del cáncer rectal. Algunos pacientes no son quirúrgicos por razones como, no ser operables o con el enfoque de ver y esperar, y en su lugar son tratados con la quimiorradiación definitiva.Utilizamos la base de datos nacional del cáncer para identificar la supervivencia general y los factores predictivos de la misma, en el tratamiento no quirúrgico de pacientes con cáncer rectal.Esta fue una revisión retrospectiva.Utilizamos los datos identificados en la base de datos nacional del cáncer.Se consultó la base de datos nacional del cáncer del 2004-2014, para adenocarcinoma rectal en estadio 1-3, tratada únicamente con quimioterapia y radiación hasta la dosis definitiva. La terapia de aumento de la dosis se definió como >54 Gy.Se realizaron análisis univariables y multivariables para identificar características sociodemográficas, de tratamiento y predictivas del aumento de la dosis y supervivencia en general. Los índices de riesgo proporcionales de Cox ajustados a la propensión para la supervivencia, se utilizaron para tener en cuenta el sesgo de indicación.Entre los 6311 pacientes elegibles para el estudio, el 11% fue tratado con dosis >54 Gy. Los pacientes en estadios tempranos y con mayor edad/comorbilidad, tenían más probabilidades de recibir aumento de la dosis, y menos propensos los pacientes con tratamientos recientes y de centros académicos. El tiempo medio de seguimiento fue de 31 meses (2-154 meses). Las tasas de supervivencia global de tres y cinco años para todos los pacientes, fueron respectivamente del 60% y 46%. Los pacientes tratados con aumento de la dosis, tuvieron una supervivencia media de 33 meses, en comparación con los 56 meses para los pacientes tratados con ≤54 Gy (p < 0,0001).La principal limitación es el inherente sesgo en la selección, presente en los estudios de la base de datos nacional del cáncer. Faltan los detalles importantes del tratamiento y los resultados en relación con el enfoque definitivo de quimiorradiación en cáncer rectal. Tampoco se registró la terapia de rescate, que en esta población podría ser la cirugía.En este análisis, el aumento de la dosis en el manejo no quirúrgico del cáncer rectal, se asoció con una menor supervivencia global, en comparación con la dosis más convencional. La cuidadosa selección del paciente y la inscripción en los apropiados ensayos clínicos, pueden estar justificados en el entorno no quirúrgico. Vea el Resumen del Video en http://links.lww.com/DCR/B15.

---

### Basal cell skin cancer, version 2.2024, NCCN clinical practice guidelines in oncology [^90531269]. Journal of the National Comprehensive Cancer Network (2023). High credibility.

Regarding medical management for basal cell carcinoma - NCCN, more specifically with respect to management of advanced basal cell carcinoma (general principles), NCCN 2023 guidelines recommend to offer the following treatment options for patients with metastatic basal cell carcinoma:

- systemic therapy

- consider offering radiation therapy or surgery for limited metastatic disease under highly selective circumstances, in the context of multidisciplinary consultation, resection of limited metastases

- offer palliation and best supportive care.

---

### Basal cell skin cancer, version 2.2024, NCCN clinical practice guidelines in oncology [^888cc71f]. Journal of the National Comprehensive Cancer Network (2023). High credibility.

Regarding medical management for basal cell carcinoma - NCCN, more specifically with respect to management of advanced basal cell carcinoma (general principles), NCCN 2023 guidelines recommend to offer the following treatment options for patients with advanced basal cell carcinoma with nodal disease:

- surgery with or without adjuvant radiation therapy

- if surgery is not feasible, then offer radiation therapy or systemic therapy

- offer participation in a clinical trial.

---

### ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients [^5d7b70a7]. Clinical Microbiology and Infection (2014). Low credibility.

Healthcare-associated infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB) are a leading cause of morbidity and mortality worldwide. These evidence-based guidelines have been produced after a systematic review of published studies on infection prevention and control interventions aimed at reducing the transmission of MDR-GNB. The recommendations are stratified by type of infection prevention and control intervention and species of MDR-GNB and are presented in the form of 'basic' practices, recommended for all acute care facilities, and 'additional special approaches' to be considered when there is still clinical and/or epidemiological and/or molecular evidence of ongoing transmission, despite the application of the basic measures. The level of evidence for and strength of each recommendation, were defined according to the GRADE approach.

---

### Ceftazidime [^e4beec44]. FDA (2024). Medium credibility.

Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used.

Ceftazidime for injection, USP may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

---

### ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer [^fa7eb663]. Annals of Oncology (2021). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of metastatic breast cancer (systemic therapy, triple-negative), ESMO 2021 guidelines recommend to offer chemotherapy in combination with an immune checkpoint inhibitor as the preferred treatment in patients with PD-L1-positive disease:

- atezolizumab plus nab-paclitaxel in case of PD-L1 immune cell positivity if the disease-free interval is ≥ 12 months.

---

### Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up [^7db2a59e]. Annals of Oncology (2024). High credibility.

Regarding medical management for breast cancer, more specifically with respect to management of early breast cancer, adjuvant systemic therapy, HER2+, ESMO 2024 guidelines recommend to consider offering extended treatment with neratinib (concurrent with endocrine therapy) for 1 year after completion of 1 year of trastuzumab or trastuzumab-based therapy in patients with high-risk HR+ breast cancer.

---

### Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update [^0e675e9d]. Journal of Clinical Oncology (2006). Low credibility.

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

---

### State of the management of infections caused by multidrug-resistant Gram-Negative organisms [^f649a2e3]. Clinical Infectious Diseases (2023). Medium credibility.

In the past decade, the prevalence of multidrug-resistant gram-negative (MDR-GN) bacterial infections has increased significantly, leading to higher rates of morbidity and mortality. Treating these infections poses numerous challenges, particularly when selecting appropriate empiric therapy for critically ill patients for whom the margin for error is low. Fortunately, the availability of new therapies has improved the treatment landscape, offering safer and more effective options. However, there remains a need to establish and implement optimal clinical and therapeutic approaches for managing these infections. Here, we review strategies for identifying patients at risk for MDR-GN infections, propose a framework for the choice of empiric and definitive treatment, and explore effective multidisciplinary approaches to managing patients in the hospital while ensuring a safe transition to outpatient settings.

---

### Tratamiento del Cáncer de mama (...) [^d3714ed4]. NCI (2025). Medium credibility.

- Recibir cualquiera de los siguientes tratamientos:
- Tener menos exposición del tejido de la mama a los estrógenos que produce el cuerpo debido a los siguientes motivos:
- Embarazo a edad temprana.
- Lactancia materna.
- Hacer suficiente ejercicio físico.
- Someterse a cualquiera de los siguientes procedimientos:
- Mastectomía para disminuir el riesgo de cáncer.
- Ooforectomía para disminuir el riesgo de cáncer.
- Ablación ovárica. Si hay más genes HER2/neu o concentraciones más altas de la proteína HER2/neu que lo normal, el cáncer se describe como positivo para HER2/neu o positivo para HER2. Este tipo de cáncer puede crecer más rápido y es más probable que se disemine a otras partes del cuerpo. El cáncer se trata con medicamentos dirigidos a la proteína HER2/neu, como el trastuzumab y el pertuzumab. Ciertos factores afectan el pronóstico y las opciones de tratamiento. El pronóstico y las opciones de tratamiento dependen de los siguientes aspectos: .

Se extrae el primer ganglio linfático que recibe la sustancia o el tinte. Un patólogo observa el tejido al microscopio para detectar células cancerosas. Si no se detectan células cancerosas, quizá no se necesite extirpar más ganglios linfáticos. A veces, se encuentra un ganglio linfático centinela en más de un grupo de ganglios linfáticos. Hay tres tipos de grupos de estadios para el cáncer de mama: Estadio clínico pronóstico: primer estadio que se asigna a todoslos pacientes según la información sobre antecedentes médicos, el examen físico, las pruebas con imágenes y las biopsias. El estadio clínico pronóstico se describe de acuerdo con el sistema de estadificación TNM, el grado del tumor y la detección de biomarcadores.
- N1mi: el cáncer se diseminó a los ganglios linfáticos axilares y mide más de 0, 2 mm pero no más de 2 mm.
- N1a: el cáncer se diseminó hasta 1 a 3 ganglios linfáticos axilares, y el cáncer de por lo menos 1 de los ganglios linfáticos mide más de 2 mm.

---

### Clinical impact of the COVID-19 pandemic in Mexican patients with thoracic malignancies [^65097ef8]. The Oncologist (2021). Medium credibility.

Background

Accumulated evidence indicates that patients with lung cancer are a vulnerable population throughout the pandemic. Limited information is available in Latin America regarding the impact of the pandemic on medical care. The goal of this study was to describe the clinical and social effect of COVID-19 on patients with thoracic cancer and to ascertain outcomes in those with a confirmed diagnosis.

Materials and Methods

This cohort study included patients with thoracic neoplasms within a single institution between March 1, 2020, and February 28, 2021. All variables of interest were extracted from electronic medical records. During this period, the Depression Anxiety and Stress Scale 21 (DASS-2) was applied to evaluate and identify more common psychological disorders.

Results

The mean age for the total cohort (n =548) was 61.5 ±12.9years; non-small cell lung cancer was the most frequent neoplasm (86.9%), advanced stages predominated (80%), and most patients were under active therapy (82.8%). Any change in treatment was reported in 23.9% of patients, of which 78.6% were due to the COVID-19 pandemic. Treatment delays (≥7days) were the most frequent modifications in 41.9% of cases, followed by treatment suspension at 37.4%. Patients without treatment changes had a more prolonged progression-free survival and overall survival (hazard ratio [HR] 0.21, p < .001 and HR 0.28, p < .001, respectively). The mean DASS-21 score was 10.45 in 144 evaluated patients, with women being more affected than men (11.41 vs. 9.08, p < .001). Anxiety was reported in 30.5% of cases, followed by depression and distress in equal proportions (18%). Depressed and stressed patients had higher odds of experiencing delays in treatment than patients without depression (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.53-13.23, p = .006 and OR 3.18, 95% CI 1.2-10.06, p = .006, respectively).

Conclusion

Treatment adjustments in patients with thoracic malignancies often occurred to avoid COVID-19 contagion with detrimental effects on survival. Psychological disorders could have a role in adherence to the original treatment regimen.

Implications For Practice

The pandemic has placed an enormous strain on health care systems globally. Patients with thoracic cancers represent a vulnerable population, with increased morbidity and mortality rates. In Mexico, treatment modifications were common during the pandemic, and those who experienced delays had worse survival outcomes. Most treatment modifications were related to a patient decision rather than a lockdown of health care facilities in which mental health impairment plays an essential role. Moreover, the high case fatality rate highlights the importance of improving medical care access. Likewise, to develop strategies facing future threats that may compromise health care systems in non-developed countries.

---

### GEICAM guidelines for the management of patients with breast cancer during the COVID-19 pandemic in Spain [^81c7c4bd]. The Oncologist (2020). Medium credibility.

Abstract

Breast cancer (BC) is the most common cancer in women in Spain. During the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus, patients with BC still require timely treatment and follow‐up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in‐hospital visit to minimize pandemic‐associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the lack of evidence about COVID‐19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing.

Implications for Practice

This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare.

---

### Haemodialysed patient with lung cancer in the COVID-19 era: a clinical challenge [^01756c97]. BMJ Case Reports (2021). High credibility.

A 66-year-old man was referred to the oncological pneumology consultation due to a mass in the right upper lobe observed in a routine X-ray of the chest. The CT scan confirmed a mass in the same location. The biopsy revealed a lung adenocarcinoma. It was decided to start chemotherapy adapted to kidney function. In April 2020, the patient contracted SARS-CoV-2 infection and developed bilateral pneumonia with partial respiratory failure. He was transferred to the intensive care unit, where he had a positive evolution. In the next 5 months, there was a clinical improvement; however, the CT scan of the chest showed disease progression. After a new multidisciplinary approach, it was decided to start a second line with atezolizumab. After four cycles of atezolizumab, there was a clear clinical improvement, and a reduction by more than 50% in the tumour size, without significant adverse effects.

---

### Guidance statement for the management of febrile neutropenia in pediatric patients receiving cancer-directed therapy in central America and the caribbean [^ff8b4765]. JCO Global Oncology (2020). Medium credibility.

INTRODUCTION

Infections are the leading causes of morbidity and mortality in pediatric patients treated for cancer in low- and low-middle-income countries (LMICs).A lack of process standardization contributes significantly to poor infectious outcomes. As part of the Prevencionistas e Infectólogos para Cáncer Infantil en América Latina (PRINCIPAL) network, infectious disease–associated health care providers in Central American and Caribbean countries identified the formation of a fever management guideline as a regional priority. A needs assessment survey of this network and related societies revealed management discrepancies and concern that international guidelines may not be regionally applicable because of differences in infectious etiologies and diagnostic and treatment resources (unpublished data). To address this issue, a multinational group conducted a formal guideline development process.

---

### Summary report of the standards, options and recommendations for the management of patients with non-small-cell lung carcinoma (2000) [^0d8f4af2]. British Journal of Cancer (2003). Low credibility.

In France, primary lung cancer (all types combined) is the leading cause of cancer mortality in men, and the third in women, after breast and colorectal cancer. In 1995, lung cancer was responsible for 23.5% of cancer deaths in men and 6.4% in women. The incidence of lung cancer is higher in men than in women, and the mortality rate is nine times higher in men than in women. The lung cancer mortality rate is constantly increasing in France, particularly in the north of the country. The increase in incidence between 1975 and 1995 was more marked in women. In France, the 5-year survival rates (11.5% for men and 16% for women) are among the highest in Europe.

---

### Guideline-recommended chemoradiation for patients with rectal cancer at large hospitals: a trend in the right direction [^a2cf282c]. Diseases of the Colon and Rectum (2019). Medium credibility.

Background

Many patients with rectal cancer are treated at small, low-volume hospitals despite evidence that better outcomes are associated with larger, high-volume hospitals.

Objectives

This study aims to examine trends of patients with rectal cancer who are receiving care at large hospitals, to determine the patient characteristics associated with treatment at large hospitals, and to assess the relationships between treatment at large hospitals and guideline-recommended therapy.

Design

This study was a retrospective cohort analysis to assess trends in rectal cancer treatment.

Settings

Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Patterns of Care studies were used.

Patients

The study population consisted of adults diagnosed with stages II/III rectal cancer in 1990/1991, 1995, 2000, 2005, 2010, and 2015.

Main Outcome Measures

The primary outcome was treatment at large hospitals (≥500 beds). The receipt of guideline-recommended preoperative chemoradiation therapy and postoperative chemotherapy was assessed for patients diagnosed in 2005+.

Results

Two thousand two hundred thirty-one patients were included. The proportion treated at large hospitals increased from 19% in 1990/1991 to 27% in 2015 (ptrend < 0.0001). Black race was associated with treatment at large hospitals (vs white) (OR, 1.73; 95% CI, 1.30-2.31), as was being 55 to 64 years of age (vs 75+), and diagnosis in 2015 (vs 1990/1991). Treatment in large hospitals was associated with twice the odds of preoperative chemoradiation, as well as younger age and diagnosis in 2010 or 2015 (vs 2005).

Limitations

The study did not account for the change in the number of large hospitals over time.

Conclusions

Results suggest that patients with rectal cancer are increasingly being treated in large hospitals where they receive more guideline-recommended therapy. Although this trend is promising, patients receiving care at larger, higher-volume facilities are still the minority. Initiatives increasing patient and provider awareness of benefits of specialized care, as well as increasing referrals to large centers may improve the use of recommended treatment and ultimately improve outcomes. See Video Abstract at http://links.lww.com/DCR/A994. QUIMIORRADIACIÓN RECOMENDADA EN GUÍAS PARA PACIENTES CON CÁNCER RECTAL EN HOSPITALES DE GRAN TAMAÑO: UNA TENDENCIA EN LA DIRECCIÓN CORRECTA: Muchos pacientes con cáncer rectal se tratan en hospitales pequeños y de bajo volumen a pesar de evidencia de que los mejores resultados se asocian con hospitales más grandes y de gran volumen.

Objetivos

Examinar las tendencias en los pacientes con cáncer rectal que reciben atención en hospitales de gran tamaño, determinar las características de los pacientes asociadas con el tratamiento en hospitales grandes y evaluar la relación entre el tratamiento en hospitales grandes y la terapia recomendada en guías. DISEÑO:: Este estudio fue un análisis de cohorte retrospectivo para evaluar las tendencias en el tratamiento del cáncer de recto.

Escenario

Se utilizaron datos de los estudios del programa Patrones de Atención, Vigilancia, Epidemiología y Resultados Finales (SEER) del Instituto Nacional de Cáncer (NIH).

Pacientes

La población de estudio consistió en adultos diagnosticados con cáncer rectal en estadio II / III en 1990/1991, 1995, 2000, 2005, 2010 y 2015.

Principales Medidas De Resultado

El resultado primario fue el tratamiento en hospitales grandes (≥500 camas). La recepción de quimiorradiación preoperatoria recomendada según las guías y la quimioterapia posoperatoria se evaluaron para los pacientes diagnosticados en 2005 y posteriormente.

Resultados

Se incluyeron 2,231 pacientes. La proporción tratada en los hospitales grandes aumentó del 19% en 1990/1991 al 27% en 2015 (ptrend < 0.0001). La raza afroamericana se asoció con el tratamiento en hospitales grandes (vs. blanca) (OR, 1.73; IC 95%, 1.30-2.31), al igual que 55-64 años de edad (vs ≥75) y diagnóstico en 2015 (vs 1990/1991). El tratamiento en los hospitales grandes se asoció con el doble de probabilidad de quimiorradiación preoperatoria, así como con una edad más temprana y diagnóstico en 2010 o 2015 (vs 2005).

Limitaciones

El estudio no tomó en cuenta el cambio en el número de hospitales grandes a lo largo del tiempo.

Conclusiones

Los resultados sugieren que los pacientes con cáncer rectal reciben cada vez más tratamiento en hospitales grandes donde reciben terapia recomendada por las guías mas frecuentemente. Aunque esta tendencia es prometedora, los pacientes que reciben atención en hospitales más grandes y de mayor volumen siguen siendo una minoría. Las iniciativas que aumenten la concientización del paciente y del proveedor de servicios médicos sobre los beneficios de la atención especializada, así como el aumento de las referencias a centros grandes podrían mejorar el uso del tratamiento recomendado y, en última instancia, mejorar los resultados. Vea el Resumen en video en http://links.lww.com/DCR/A994.

---

### El enfoque de orientación cognitiva al desempeño ocupacional diario en discapacidades con origen en la infancia [^51f13ef3]. Developmental Medicine and Child Neurology (2025). Medium credibility.

Recomendación 5. Mecanismos subyacentes del cambio

Faltan estudios que identifiquen los ingredientes activos y los mecanismos de cambio, incluidos los resultados relacionados con la transferencia, tal como se definió anteriormente. Para comprender el mecanismo de acción del enfoque CO‐OP, es necesario identificar los procesos activos y/o componentes del tratamiento y probar cómo conducen a resultados positivos. Comprender por qué funciona CO‐OP, a través de qué procesos y cómo ocurre el cambio en diferentes poblaciones, permitiría entender los mecanismos de cambio terapéutico.

Comprender si existen mediadores y moderadores específicos de la eficacia ayudará a desentrañar los mecanismos subyacentes de acción. La evidencia en neurociencias, como la comprensión de las vías de la actividad motora y cómo actúa CO‐OP en términos de vías neuronales e interacciones, podría ser útil para refinar la intervención y proporcionar tratamientos personalizados. Comprender el impacto de CO‐OP en el neurodesarrollo y en las vías cognitivas‐motoras, especialmente en niños con discapacidades complejas, podría perfeccionar el enfoque y orientar hacia tratamientos más personalizados.

---

### Colorectal cancer screening and prevention [^c270f773]. American Family Physician (2025). High credibility.

Regarding screening and diagnosis for colon cancer, more specifically with respect to indications for screening, general population, aged 76-85 years, AAFP 2025 guidelines recommend to consider obtaining screening for CRC in adults aged 76-85 years at average risk based on overall health status, prior screening history, and patient preferences.

---

### Factors predictive of mortality in a cohort of women surgically treated for breast cancer from 1997 to 2014 [^0bb70ee5]. International Journal of Gynaecology and Obstetrics (2016). Low credibility.

Objective

To determine whether previously reported factors predictive of breast cancer mortality are effectively linked with mortality, particularly breast-cancer-specific mortality.

Methods

In a prospective study, clinical, surgical, and follow-up data were assessed for consecutive patients with breast cancer who underwent surgery between 1997 and 2014 at two centers in Barcelona, Spain. Predictors of mortality were assessed by multivariate analysis.

Results

Overall, 2134 patients were treated for 2206 breast tumors. Overall mortality was 15.0% (n=319), and breast-cancer-specific mortality was 9.0% (n=191). On multivariate analysis, the most significant factors associated with breast-cancer-specific mortality were clinical stage, inmunohistochemical profile, locoregional relapse, and lymphovascular invasion (all P<0.001). Age at onset, participation in the mass-screening program, histologic grade, and multicentricity were not significant. Patients with three or more positive axillary nodes sustained a specific mortality significantly higher than did node-negative patients or those with fewer than three positive nodes.

Conclusion

Factors predictive of breast cancer mortality were clinical stage, locoregional relapse, molecular classification, lymphovascular invasion, and neoadjuvant chemotherapy. As a single factor, nodal disease becomes relevant only when three or more lymph nodes are involved.

---

### Impact of COVID-19 infection on patients with cancer: experience in a latin American country: the ACHOCC-19 study [^a317973d]. The Oncologist (2021). Medium credibility.

Abstract

Introduction

The ACHOCC‐19 study was performed to characterize COVID‐19 infection in a Colombian oncological population.

Methodology

Analytical cohort study of patients with cancer and COVID‐19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID‐19 infection were collected. The primary outcome was 30‐day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression.

Results

The study included 742 patients; 72% were >51 years. The most prevalent neoplasms were breast (132, 17.77%), colorectal (92, 12.34%), and prostate (81, 10.9%). Two hundred twenty (29.6%) patients were asymptomatic and 96 (26.3%) died. In the bivariate descriptive analysis, higher mortality occurred in patients who were >70 years, patients with lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute‐phase reactants. In the logistic regression analysis, higher mortality was associated with Eastern Cooperative Oncology Group performance status (ECOG PS) 3 (odds ratio [OR] 28.67; 95% confidence interval [CI], 8.2–99.6); ECOG PS 4 (OR 20.89; 95% CI, 3.36–129.7); two complications from COVID‐19 (OR 5.3; 95% CI, 1.50–18.1); and cancer in progression (OR 2.08; 95% CI, 1.01–4.27). In the Cox regression analysis, the statistically significant hazard ratios (HR) were metastatic disease (HR 1.58; 95% CI, 1.16–2.16), cancer in progression (HR 1.08; 95% CI, 1.24–2.61) cancer in partial response (HR 0.31; 95% CI, 0.11–0.88), use of steroids (HR 1.44; 95% CI, 1.01–2.06), and use of antibiotics (HR 2.11; 95% CI, 1.47–2.95).

Conclusion

In our study, patients with cancer have higher mortality due to COVID‐19 infection if they have active cancer, metastatic or progressive cancer, ECOG PS >2, and low socioeconomic status.

Implications for Practice

This study's findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired Eastern Cooperative Oncology Group status to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment.

---

### NCCN guidelines® insights: breast cancer, version 5.2025 [^10023331]. Journal of the National Comprehensive Cancer Network (2025). High credibility.

Preoperative chemotherapy options—According to the NCCN Panel, a number of chemotherapy regimens have activity in the preoperative setting and those regimens recommended in the adjuvant setting may be considered in the preoperative setting; in both settings, the underlying aim remains eradication or control of undiscovered distant metastases.

---

### Pathological response to neoadjuvant chemotherapy and the molecular classification of locally advanced breast cancer in a latin American cohort [^c37b0172]. The Oncologist (2019). Medium credibility.

In the meta‐analysis published in 2018 by the Early Breast Cancer Trialists’ Collaborative Group, within a population of 4,756 women with early breast cancer, 69% of the patients who received NACT had partial or complete clinical response. Additionally, a conservative breast surgery rate of 65% was achieved. At 15‐year follow‐up, a higher rate of local recurrence was observed in patients who received NACT (21.4%) versus patients who received adjuvant chemotherapy (15.9%), with an absolute difference of 5.5% (95% CI 2.4–8.6) and relative risk (RR) of 1.37 (95% CI, 1.17–1.61; p =.0001). There were no differences regarding distant recurrences (38.2% neoadjuvant vs. 38.0% adjuvant; RR, 1.02; 95% CI, 0.92–1.14; p =.66), death by cancer (34.4% vs. 33.7%; RR, 1.06; 95% CI, 0.95–1.18; p =.31), or deaths from other causes (40.9% vs. 41.2%; RR, 1.04; 95% CI, 0.94–1.15; p =.45) [9].

The purpose of this study is to describe the pathological response obtained with NACT according to the molecular classification of breast cancer in patients with locally advanced tumors treated within the National Cancer Institute (NCI) Functional Breast Cancer Unit (FBCU) in Bogotá, Colombia. Colombia is known for being a country with a mestizo and multicultural population; it is for this reason that the results could be extrapolated to the rest of the countries of the region, and treatment guidelines could be developed for breast cancer based on the findings presented in this article.

---

### Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines [^d3a8e7e1]. Chest (2013). Medium credibility.

NSCLC or carcinoid tumor after curative-intent therapy—it is recommended that the original treating physicians participate in the decisionmaking process during the follow-up and surveillance (Grade 1C).

---

### Dexamethasone intensol [^b7780bad]. FDA (2016). Low credibility.

CONTRAINDICATIONS

Contraindicated in systemic fungal infections (see WARNINGS: Infections: Fungal Infections) and patients with known hypersensitivity to the product and its consituents.

---

### Reducing patient burden and improving data quality with the new Cleveland clinic colorectal cancer quality of life questionnaire [^84fc4a45]. Diseases of the Colon and Rectum (2020). Medium credibility.

Background

The Cleveland Clinic Colorectal Cancer Quality of Life Questionnaire was developed in response to the need for a new, fast, and comprehensive tool for evaluating quality of life in patients who have colorectal cancer. Available surveys such as the SF-12, SF-36, Functional Assessment of Cancer Therapy-Colorectal, and European Organization for Research and Treatment of Cancer are either too general to be informative or too lengthy to complete.

Objective

The aim was to validate the Cleveland Clinic Foundation Colorectal Quality of Life Questionnaire.

Design

Data were obtained as part of a prospective randomized controlled trial.

Settings

This was a worldwide multicenter study with 2 domestic and 5 international locations.

Patients

This study randomly assigned 190 patients between the ages of 18 and 80 undergoing surgery for low rectal cancer. Of those randomly assigned, 142 with partially complete surveys were analyzed for selection bias and acceptability, and 95 with complete surveys were analyzed for survey validity.

Interventions

Patients received either a J-pouch, side-to-end anastomosis, or straight anastomosis.

Main Outcome Measure

The study evaluated survey validity measures such as standardized Cronbach α for internal consistency and Spearman correlation coefficients for construct validity, convergent validity, and responsiveness. Univariate analyses were used to assess discriminative validity.

Results

Sufficient acceptability, construct, and convergent validity and responsiveness were achieved. All scores showed great internal consistency (Cronbach α >0.8). Superior discriminative ability was demonstrated by significant differences (p < 0.05) in 2 of 7 scores between neoadjuvant treatment groups, and in 6 of 7 scores between complication groups, none of which were detected by the SF-12 or Functional Assessment of Cancer Therapy-Colorectal surveys.

Limitations

Limitations included a small sample size, cultural differences, and failure to assess test-retest ability of the questionnaire.

Conclusions

The Cleveland Clinic Colorectal Cancer Quality of Life Questionnaire is an efficient and reliable quality-of-life measure that better incorporates factors specific to colorectal cancer surgery. See Video Abstract at http://links.lww.com/DCR/B155. REDUCIENDO LA CARGA AL PACIENTE Y MEJORANDO LA CALIDAD DE DATOS CON EL NUEVO CUESTIONARIO DE CALIDAD DE VIDA EN CÁNCER COLORRECTAL DE CLEVELAND CLINIC (CCF-CAQL): El cuestionario de calidad de vida en cáncer colorrectal de Cleveland Clinic se desarrolló en respuesta a la necesidad de una herramienta nueva, rápida e integral para evaluar la calidad de vida en pacientes con cáncer colorrectal. Los cuestionarios disponibles como SF-12, SF-36, FACT-C y EORTC son demasiado generales para ser informativas o demasiado largas para completar.El objetivo fue validar el cuestionario de calidad de vida colorrectal de la Cleveland Clinic Foundation.Los datos se obtuvieron como parte de un ensayo prospectivo aleatorizado y controlado.Este fue un estudio multicéntrico mundial con dos sedes nacionales y cinco internacionales.Este estudio aleatorizó a 190 pacientes entre las edades de 18 y 80 sometidos a cirugía por cáncer rectal bajo. De aquellos aleatorizados, 142 con encuestas parcialmente completas se analizaron para determinar el sesgo de selección y la aceptabilidad, y 95 con encuestas completas se analizaron para determinar la validez de la encuesta.Los pacientes recibieron un reservorio en J, anastomosis latero-terminal o anastomosis termino-terminal.El estudio evaluó medidas de validez de la encuesta, como el Alfa de Cronbach estandarizado para la consistencia interna y los coeficientes de correlación de Spearman para la validez de construcción, la validez de convergencia y la capacidad de respuesta. Se utilizaron análisis univariados para evaluar la validez discriminativa.Se obtuvo suficiente aceptabilidad, construcción, validez de convergencia, y capacidad de respuesta. Todos los puntajes mostraron una gran consistencia interna (alfa de Cronbach > 0.8). Una capacidad discriminativa superior fue demostrada por diferencias significativas (p < 0.05) en dos de siete puntajes entre grupos de tratamiento neoadyuvante, y en seis de siete puntajes entre grupos de complicaciones, ninguno de los cuales fue detectado por SF-12 o FACT-C.Las limitaciones incluyeron un tamaño de muestra pequeño, diferencias culturales y la falta de evaluación de la confiabilidad test-retest del cuestionario.El Cuestionario de Calidad de Vida en Cáncer Colorrectal de Cleveland Clinic es una medida de calidad de vida eficiente y confiable que incorpora mejor factores específicos asociados a la cirugía de cáncer colorrectal. Consulte Video Resumen en http://links.lww.com/DCR/B155.

---

### Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [^f9a49be2]. Annals of Oncology (2021). High credibility.

Regarding medical management for anal cancer, more specifically with respect to management of local/locoregional disease, chemoradiotherapy, ESMO 2021 guidelines recommend to offer radiotherapy with concomitant 5-FU and mitomycin C as standard of care in patients with localized SCC of the anus.

---

### Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the neoALTTO phase III trial [^c6280be8]. Annals of Oncology (2013). Low credibility.

Background

The NeoALTTO trial showed that dual HER2 blockade nearly doubles the rate of pathologic complete response (pCR) in patients with primary HER2-positive breast cancer. However, this did not translate into a higher rate of breast-conserving surgery (BCS).

Patients and Methods

In NeoALTTO, patients with HER2-positive breast cancer were randomly assigned to either trastuzumab, lapatinib or their combination with paclitaxel before surgery with pCR as the primary end point. We investigated the association between the surgery type and clinicopathological factors and response to treatment, adjusting for the treatment arm.

Results

Four hundred and twenty-nine patients were subjected to breast surgery. Two hundred and forty-two (56%) and 187 (44%) patients underwent mastectomy and BCS, respectively. In a logistic regression model, negative estrogen receptor (ER), multicentricity and the presence of a palpable mass before surgery were significantly associated with a low chance of BCS. Conversely, patients with small tumors and those eligible for BCS at diagnosis were managed more with BCS, independent of the treatment arm. Radiological response was not associated with the surgical decision.

Conclusions

Tumor characteristics before neoadjuvant therapy play a main role in deciding the type of surgery calling for a clear consensus on the role of BCS in patients responding to neoadjuvant therapy.

---

### ABC4 consensus: first latin American meeting-assessment, comments, and application of its recommendations [^10df8dca]. JCO Global Oncology (2020). Medium credibility.

Patients experiencing PD with an anti-HER2 therapy combined with a cytotoxic or endocrine agent should be offered additional anti-HER2 therapy with subsequent treatment, unless there are contraindications (LoE: I/A).Anti-HER2 therapy for ABC must be maintained until PD, unacceptable toxicity, or patient request; however, stopping anti-HER2 therapy after several years of sustained complete remission may be considered, particularly if treatment rechallenge is available in case of PD (LoE: expert opinion).

T-DM1 improves PFS and OS (not reached v 23.3 months; P =.0005) when compared with lapatinib plus capecitabineor physician choice (PFS: 6.2 v 3.3 months; P <.0001)in patients resistant to trastuzumab, with a favorable toxicity profile (LoE: I/A). However, there are no data on its use after dual HER2 blockade.The combination of trastuzumab and lapatinib is a reasonable treatment option for patients heavily pretreated with trastuzumab, based on increased response rates and longer PFS (12.0 v 8.1 weeks; hazard ratio, 0.73; P =.008) compared with lapatinib.The combination of chemotherapy and trastuzumab plus pertuzumab could be used in a trastuzumab-refractory scenario,but there are no data on its use after PD with pertuzumab or T-DM1(LoE: I/B).

---

### Symptomatic treatment of cough among adult patients with lung cancer: CHEST guideline and expert panel report [^daa724da]. Chest (2017). Medium credibility.

CHEST guideline—adult lung cancer with persistent cough: In adult patients with cough associated with lung cancer that persists despite cancer treatment, we suggest, as a first step, that a comprehensive assessment according to a published, evidence-based management guideline be undertaken to identify any co-existing causes linked with cough and initiate treatment accordingly (Ungraded, Consensus Based Statement). The narrative emphasizes initiating management with a comprehensive assessment targeting treatable causes, notes that physicians should also differentiate between productive and nonproductive cough because the aim of treatment differs, and gives examples that causes may be treated with oncological treatment of cancer, pleural drainage, antibiotics, or steroid therapy when appropriate.

---

### Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines [^9ffb5af0]. Chest (2013). Medium credibility.

Metastatic NSCLC (stage IV disease)—biopsy target selection: In many of these patients, fine-needle aspiration (FNA) or needle biopsy of a site of metastasis represents the most efficient way to both make a diagnosis and confirm the stage.

---

### ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer [^3f92e378]. ESMO Open (2025). High credibility.

Regarding medical management for pancreatic cancer, more specifically with respect to management of advanced/metastatic disease, first-line therapy, ESMO 2025 guidelines recommend to consider offering gemcitabine plus nab-paclitaxel as an alternative option in patients with metastatic pancreatic cancer.

---